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 My research interest is the intersection of communicable and non-communicable 
(chronic) disease. Human immunodeficiency virus (HIV) infection and coronary heart disease 
(CHD) provide an interesting model to study this intersection because 1) treated HIV infected 
people are living long enough to die from non-AIDS causes 2) ischemic heart disease is the 
leading cause of death worldwide and 3) HIV/AIDS is among the top 10 causes of death. It is 
therefore of public health importance to examine the mechanisms by which HIV contributes to 
CHD. This dissertation focuses on the roles that co-morbdity and inflammation play within this 
intersection. 
The first intersection, lipid and lipoprotein dysregulation, is a great place to start because 
it 1) co-occurs with HIV (and other) infections, 2) is an important risk factor for atherosclerotic 
CHD and 3) is modifiable with existing, inexpensive therapy. We review lipid and lipoprotein 
metabolism alterations in untreated HIV infection.  
The second intersection is inflammation, an immune response process and an integral 
component of atherosclerosis. Prior work was limited by comparisons of inflammatory 
biomarkers in HIV infected and (typically healthier) uninfected populations from different 
cohorts and limited adjustment for comorbid conditions that also influence these biomarkers. 
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ABSTRACT 
 v 
Paper 1 compares inflammatory biomarkers between HIV infected and behaviorally and 
demographically similar uninfected Veterans with similar burdens of comorbid disease. 
The third intersection focuses on other diseases co-morbid with HIV that also contribute 
to CHD risk. Specifically, Paper 2 compares inflammatory biomarkers between HIV infected 
people with or without hepatitis C co-infection as an example of HIV-related comorbidity. Paper 
3 compares risk for acute myocardial infarction by blood pressure and HIV status as an example 
of comorbidity that is not directly related to HIV infection. 
In summary, this dissertation contributes insights into the pathogenesis of CHD in the 
setting of HIV infection. It emphasizes the importance of studying HIV as a disease with 
pleiotropic effects (on biomarkers and organ systems) that can interact with each other, 
modifying their independent contributions to CHD risk. 
. 
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1.0  LITERATURE REVIEW: HIV INFECTION AND DYSREGULATION OF LIPID 
& LIPOPROTEIN METABOLISM 
People with human immunodeficiency virus (HIV) may be at increased risk for coronary 
heart disease (CHD) due at least in part to pro-atherogenic lipid and lipoprotein dysregulation 
associated with the virus and its treatment. This lipid and lipoprotein dysregulation occurs as part 
of the host’s normal immune response 1. There is a net beneficial effect of acute lipid 
dysregulation to the host. However, with chronic infections such as HIV, comes chronic 
dysregulation of lipids and lipoproteins, some of which are associated with atherosclerotic heart 
disease. To understand the contribution of HIV to CHD via an atherosclerotic mechanism, it is 
important to understand exactly how HIV infection alters lipid and lipoprotein metabolism 
independently of antiretroviral therapy (ART). We hypothesize that a difference in etiology of 
lipid dysregulation in HIV infected persons compared to uninfected persons may result in 
different effects of lipid dysregulation on CHD risk and may require different approaches to 
treating lipid dysregulation in HIV infection. 
  
2 
1.1 AIMS 
We conducted a literature review with two aims: 1) to describe HIV-related changes in 
the rates of synthesis and clearance of serum lipids and lipoproteins independently of ART, 2) to 
describe how HIV-related changes in serum lipid/lipoprotein metabolism alter the content and 
distribution of cellular lipids. We propose a mechanism wherein HIV may benefit from the 
chronic dysregulation in lipid and lipoprotein metabolism. 
 
1.2 METHODS 
We searched PubMed on 08/07/2012. We created searches to define the following 
concepts (Table A1): lipids/lipoproteins, HIV, kinetic studies, HIV uninfected, antiretroviral 
therapy naïve, title pertaining to lipids or lipoproteins, hypertriglyceridemia, elevated free fatty 
acids (FFAs), high density lipoprotein (HDL), HDL- triglycerides, low or very low density 
lipoprotein (LDL, VLDL), LDL- or VLDL- cholesterol reduction, LDL or VLDL triglycerides, 
cell membrane structure.  
For Aim 1, we combined the search concepts for lipids and lipoproteins, HIV, kinetic 
studies with those for 1) HIV uninfected or 2) antiretroviral therapy naïve or 3) title pertaining to 
lipids or lipoproteins. We then discarded abstracts that were either irrelevant to lipid/lipoprotein 
kinetics in HIV, described lipid/lipoprotein responses to drug therapy, or did not have an HIV 
uninfected or antiretroviral therapy naïve control group. We selected articles that investigated the 
independent effect of HIV on lipid/lipoprotein kinetics.  
3 
For Aim 2, we combined the search concepts for hypertriglyceridemia, elevated FFAs, 
HDL/LDL/VLDL cholesterol reduction, and HDL/LDL/VLDL triglycerides with the concepts 
for cell membrane structure. We selected articles that described how changes in serum lipids 
concentrations affect cellular lipid concentrations and distribution. 
1.3 RESULTS 
1.3.1 The bigger picture – infection and changes in metabolism  
The literature on changes in protein and energy metabolism following infection is vast. A 
consistent pattern of negative protein and energy balance has been associated with localized and 
systemic infections by different pathogens 
2-5
. This is relevant to this literature review because 
lipoproteins, as their names suggest, are proteins, and lipids, such as triglycerides, are energy 
sources.  
AIDS patients receiving total parenteral nutrition have been shown not to gain lean body 
mass when an active secondary infection was present 
6
. This highlights an important difference 
between the metabolic effects of infection versus malnutrition. Macallan et al demonstrated an 
increase in whole body protein turnover in HIV infected versus uninfected persons 
7
. 
Asymptomatic ART-naïve HIV infection has been associated with 7-15% increase in resting 
energy expenditure 
8,9
, with higher levels reported amongst AIDS patients 
10,11
. Other work has 
reported reduced energy intake, rather than elevated total daily energy expenditure, as the driving 
factor behind weight loss in HIV-associated wasting 
12
. Additionally, infections co-morbid with 
HIV, such as hepatitis C and tuberculosis also have effects of on energy metabolism 
13,14
. 
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This context of metabolic alterations is necessary to understand that the alterations in 
lipids and lipoproteins presented below are occurring as part of a larger set of metabolic changes 
that accompany infection.  
1.3.2 A brief primer on lipid and lipoprotein metabolism  
Cells need lipids to maintain their structure and as an alternate source of energy to 
glucose. Lipids are obtained exogenously (from diet) or endogenously (primarily synthesized in 
the liver). Lipids are transported to and from cells by lipoproteins. Lipoproteins are often 
distinguished by the apolipoproteins with which they are associated. 
The endogenous and exogenous pathways of lipid and lipoprotein metabolism are 
summarized in Figure 1
15
. In the exogenous pathway, dietary cholesterol and esterified 
triglycerides are combined with apolipoprotein B-48 (apoB-48), phospholipid, and free 
cholesterol to create chylomicrons in intestinal cells. Chylomicrons acquire apoliporotein E 
(apoE) and apolipoprotein C (apoC) from other lipoproteins and lose triglycerides (delipidation 
via the action of lipoprotein lipase (LPL)) to form chylomicron remnants. Chylomicron remnants 
are removed from circulation by the liver via the interaction between LDL-related protein, LDL-
receptors, and hepatic apoE and apoB receptors.  
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Figure 1. Exogenous and endogenous pathways of lipid and lipoprotein metabolism. Copied with permission 
from Chang et al 
15
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Triglycerides and cholesterol synthesized endogenously are transported into circulation 
by VLDL. VLDL is broken down to form VLDL remnants, intermediate density lipoprotein 
(IDL) (transiently) or LDL via LPL or hepatic lipase action. LDL cholesterol is taken up into 
extrahepatic tissue via the interaction between apoB-100 and LDL receptors on plasma 
membranes. LDL cholesterol, VLDL remnants and IDL-cholesterol that are not taken up by 
extrahepatic cells are returned to the liver via interaction with VLDL receptors, LDL-related 
protein and apoB-100 or apoE (for IDL). Unused cholesterol from within extrahepatic cells is 
effluxed by HDL through the action of reverse cholesterol transport mediated by apolipoprotein 
A-I (apoA-I) and apolipoprotein A-I (apoA-II). Free cholesterol in HDL is taken up by the liver 
via scavenger receptor BI (SR-BI) while esterified HDL-cholesterol can be transferred to VLDL, 
IDL or LDL via cholesterol ester transfer protein (CETP) in exchange for triglycerides. 
1.3.3 A brief primer on stable isotope kinetic studies  
The information in this primer is mainly summarized from a review by Chan et al 
15
. 
Stable isotope kinetic studies allow us to quantify lipid and lipoprotein metabolism. For them 
studies to describe the synthesis and breakdown of these particles, a tracer and a trace are 
needed. A tracer is a moiety involved in the kinetics of the system under investigation. A tracee 
is used to track the tracer. For example, Apo-B100 remains associated with VLDL, IDL, and 
LDL and so is a suitable tracee for these lipoproteins. Apo-AI and apo-AII, though not 
permanently associated with HDL, still make for suitable tracees with the help of isotopically 
labeled amino acids (tracers) and compartment modeling.  
Compartment models partition a biological system into a set of interconnected 
compartments through which tracees and their associated tracers move and are tracked. Stable 
7 
isotope tracers like 
2
H and 
13
C labeled leucine are injected into a subject and endogenously 
incorporated into apolipoproteins (and subsequently lipoproteins), or other tracees of interest. 
Mathematical (differential) equations are used to model the movement of labeled lipoproteins 
through the compartments of the system enabling description of the kinetics of the metabolic 
pathways involved in the system. The concepts of endogenous labeling and compartment models 
are illustrated in Figure 2 and Figure 3
15
. 
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Figure 2. Endogenous isotopic labeling. Copied with permission from Chang et al. 
15
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Figure 3. Compartment models. Copied with permission from Chang et al
15
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Outcomes from kinetic studies include absolute or fractional synthetic rates (ASR, FSR), 
fractional catabolic rate (FCR), clearance rate, secretion rate residence time, percentage uptake, 
and counts per minute (defined in Table 1). 
 
Table 1: Definitions of outcomes from stable isotope kinetic studies 
Outcome Definition 
Pool Compartment 
Pool size The mass of tracee in a specific compartment determined as 
the product of plasma volume and trace concentration   
Fractional synthetic rate (FSR) The rate of incorporation of a precursor into a product per unit 
of product mass. Calculated as quotient of initial rate of 
change of in product enrichment and initial precursor 
enrichment  
Absolute synthetic rate (ASR) Product (mathematical) of FSR and mass of product  
Fractional catabolic rate (FCR) The fraction of tracee irreversibly removed from a 
compartment per unit of time.  
Clearance rate The rate at which the tracee leaves the pool.  
Secretion rate The rate at which the tracee enters the pool. Derived from the 
product of FCR and tracee pool size.  
Residence time Inverse of FCR 
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1.3.4 Effects of HIV infection on blood lipid and lipoprotein kinetics.  
Aim 1 was to describe HIV-related changes in the rates of synthesis and clearance of 
blood lipids and lipoproteins independently of antiretroviral therapy (ART). We found six 
studies that met criteria for Aim 1 and included 2 additional studies due to the scarcity of data on 
HDL kinetics in this population (Table 2). All selected studies had HIV-uninfected control 
groups. Three studies explicitly included HIV treatment naïve participants 
16-18
, one study was 
conducted before widespread availability of antiretroviral therapy 
19
, and two studies were 
conducted in vitro 
20,21
. The two studies that examined HDL kinetics were included though they 
did not include ART-naïve subjects 
22,23
. Sample sizes ranged from 5 – 40 participants and 
matching, if performed, was often based primarily on age and gender.  
Grunfeld et al published early data indicating slower triglyceride clearance in 
(presumably untreated) AIDS participants compared to age and gender matched uninfected 
participants 
19
. Umpleby et al showed that HIV infection decreased synthesis of LDL in 
untreated HIV infected people compared to uninfected people, although treated individuals 
experienced decreased breakdown of LDL allowing it to remain in circulation for a longer time 
17
. In this study, controls were younger (~33 vs. 40 years), less likely to be male, and had slightly 
lower mean BMI (~23 vs. 24 kg/m
2
). Participants were predominantly Caucasian.  
In response to graded glucose infusion, ART treatment-naïve individuals had higher 
plasma FFA levels and plasma triglyceride levels than did uninfected individuals. This difference 
was maintained after ART initiation and eight weeks of treatment 
18
. This group also showed that 
secretion rates for apolipoprotein-B associated with very low-density lipoproteins (VLDL-apoB) 
and VLDL-triglyceride were lower in treatment-naïve HIV-infected versus uninfected 
12 
participants though the rates were similar after ART initiation among infected participants 
18
. 
The fractional catabolic rate (FCR) and clearance of VLDL-apoB and VLDL-TG were also 
lower in treatment-naïve HIV infected versus uninfected participants, a finding that persisted 
eight weeks after initiation of ART 
18
. Again, controls were younger (31 vs. 41 years) with 
slightly lower mean BMI (22.5 vs. 24.5 kg/m
2;
 p=0.12).  
Shahmanesh et al reported no significant differences in lipid kinetics between treatment-
naïve infected individuals and uninfected individuals 
16
. However, in treated individuals, VLDL-
apoB and intermediated-density lipoprotein-apoB (IDL-apoB) FCRs were lower, while absolute 
secretion rates (ASRs) were similar and consequently residence times were higher compared to 
uninfected individuals 
16
. Participants were predominantly white and controls were again 
younger  (~33 vs. 40 years) and more likely to be female.   
In two separate studies 
22
 
23
, Jahoor et al showed higher FSR of HDL-apoA1 in treated 
HIV-infected males and children compared to uninfected controls. In both studies, there was no 
difference in ASR of HDL-apoA1 by HIV status. In the adult study, controls were younger (35 
vs. 40 years) and had lower mean BMI (21 vs. 24 kg/m
2
), whereas in the pediatric study, the 
controls were less likely to be malnourished. 
In-vitro data showed decreased synthesis of lipid precursors (phosphatidylcholine, 
phosphatidylinositol, phosphatidylethanolamine) and major lipid synthetic intermediates 
(phosphatidic acid, diacylglycerol (DAG)) in human T-lymphotrophic virus type III (HTLVIII) 
infected versus uninfected ERIC cells (CD4+ T-cell line susceptible to HIV cytopathology). 
There was, however, increased synthesis of neutral lipids (triglycerides, cholesterol esters) in 
these cells 
21
. A separate in-vitro study found increased synthesis of DAG, 1-alkyl-2-acyl-sn-
13 
glycerol (AAG) [both diglycerides], and ceramide (a glycosphingolipid) after eight days of 
HTLV-III infection of CEM cells (human leukemia cell line).  
With regard to serum/plasma lipids, these studies described lower or similar total 
cholesterol, HDL-cholesterol, LDL-cholesterol and apo-B100, and higher or similar triglycerides 
in infected versus uninfected individuals. 
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Table 2: Summary of articles selected for literature review describing effects of HIV infection on lipid and lipoprotein metabolism 
Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
2005 
16 
Overnight fast, baseline 
blood sample, 1-13C 
Leucine infusion (9 
hours), blood samples 
during infusion every 30 
minutes 
 
Exclusions include 
Fasting glucose 
>6mmol/L, lipid altering 
drugs, elevated liver 
enzymes, recent weight 
loss ≥10% 
 
 
40 HIV+ ART-
treated 
15 PI+, 25 (PI-) 
Current CD4: 
435±187 (PI+), 
469±265 (PI-))  
Pre-ART HIV 
RNA (log 
copies/ml): 
5.12±0.54 (PI+), 
4.83±0.74 (PI-)  
 
15 HIV+ 
treatment naïve 
(TN). Current 
CD4: 367±222) 
HIV RNA (log 
copies/ml): 
4.39±0.76 
HIV 
duration: not 
reported 
 
ART 
duration  
PI+: 4.1±1.2 
PI-: 2.6±0.2 
VLDL-apoB100, 
IDL-apoB100,  
 
Plasma total 
VLDL-c, IDL-c, 
VLDL-TG, IDL-
TG, HDL-c, LDL-
c  
 
Nonesterified fatty 
acids (NEFA) 
Lower plasma HDL-c and higher IDL-TG in TN 
HIV+ vs. HIV- 
No difference in other plasma lipoprotein-
cholesterol in TN HIV+ vs. HIV- 
Lower plasma HDL-c and higher TG, IDL-TG and 
IDL-c in PI group vs. HIV- 
Lower plasma HDL-c and higher TG in (PI-) group 
vs. HIV- 
No difference in NEFA between any HIV+ vs. 
HIV- 
No significant differences in lipid kinetics between 
TN HIV+ and HIV-  
VLDL-apoB and IDL-apoB FCRs were lower in 
the treated groups vs. HIV- 
No significant differences in VLDL-apoB and IDL-
apoB ASRs in treated groups vs. HIV- 
VLDL-apoB and IDL-apoB residence times were 
higher in the treated groups vs. HIV- 
12 presumed 
uninfected(high 
HIV risk 
individuals 
required negative 
test within prior 3 
months) 
15 
Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
1992 
19 
Standardized diet, 
overnight fast, plasma 
sampling, heparin 
administration, plasma 
sampling (7 samples over 
50 minutes)  
 
Exclusions include  
Diabetes, renal failure, 
nephrotic syndrome, 
active hepatitis, cirrhosis, 
lipid altering drugs 
29 HIV+ 
including 
14 HIV+ without 
history of 
opportunistic 
infection or 
malignancy, and  
15 HIV+ with 
AIDS 
HIV duration 
not reported 
 
ART 
duration not 
reported; 
Study likely 
completed 
before 
widespread 
availability 
of ART 
TG, HDL-c, 
HDL2-c, HDL3-c, 
apo-A1, apo-B100, 
calculated LDL-c 
and VLDL-c, 
postheparin lipase, 
FFA 
 
TG, cholesterol, 
phospholipid and 
protein content of 
HDL LDL and 
VLDL 
Higher plasma TG in AIDS vs. HIV+, AIDS vs. 
HIV- but not HIV+ vs. HIV- 
Lower serum cholesterol in AIDS and HIV+ vs. 
HIV- 
Lower HDL-c, HDL2-c, HDL3-c, and apo-A1 in 
AIDS and HIV+ vs. HIV- 
Lower LDL in AIDS and lower apo-B100 in AIDS 
and HIV+ vs. HIV- 
Higher calculated VLDL in AIDS vs. HIV+, AIDS 
vs. HIV- but not HIV+ vs. HIV- 
Higher FFA in AIDS vs. HIV+, AIDS vs. HIV- but 
not HIV+ vs. HIV- 
Slower clearance of TG-rich particles in AIDS vs. 
HIV+, AIDS vs. HIV-, and HIV+ vs. HIV- 
Significant correlation between TG clearance time 
and TG levels  
Higher LDL-TG and lower LDL-phospholipid 
content but similar LDL-c and LDL-protein content 
in AIDS vs. HIV- 
Higher HDL-TG and lower HDL-c content but 
similar HDL-protein and HDL-phospholipid 
content in AIDS vs. HIV- 
No difference in VLDL composition in AIDS vs. 
HIV- 
No difference in LDL-TG or HDL-TG content in 
HIV+ vs. HIV- (data not shown) 
Lower concentrations of total, hepatic (AIDS only) 
and lipoprotein lipase in AIDS and HIV+ vs. HIV- 
16 HIV antibody 
negative age- and 
gender-matched 
uninfected  
16 
Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
2005 
17 
 
Overnight fast, baseline 
blood sample, 1-13C 
leucine infusion (9 
hours), blood samples 
during infusion every 60 
minutes 
 
Exclusions included 
Fasting glucose 
>6mmol/L, lipid altering 
drugs, elevated liver 
enzymes, recent weight 
loss ≥10% 
39 HIV+ ART 
treated 
15 PI+, 24 (PI-): 
Current CD4: 
435±187(PI+), 
479±266 (PI-);  
Pre ART HIV 
RNA (log 
copies/ml): 
5.1±0.5 (PI+), 
4.8±0,8 (PI-)  
 
13 HIV+ 
treatment naïve 
(TN). Current 
CD4: 377±238; 
HIV RNA (log 
copies/ml): 
4.3±0.8 
HIV duration 
not reported 
 
ART (PI+): 
4.1±1.2, 
ART(PI-): 
2.6±1.2 
Plasma total LDL-
c, LDL-TG, HDL-
c, LDL-apoB100, 
oxidized LDL 
(oxLDL) 
 
Nonesterified fatty 
acids (NEFA) 
No difference in plasma TG in TN vs. HIV- 
Higher plasma TG in PI+ but not PI- vs. HIV- 
Lower HDL-c in all HIV+ groups vs. HIV- 
No difference in LDL-c, LDL-c/apoB ratio, LDL-
TG, LDL-TG/apoB ratio, oxLDL/apoB ratio or 
NEFA by HIV status 
Lower LDL-ASR in TN and treated HIV+ vs. HIV- 
Lower LDL-FCR and higher LDL-RT in treated 
HIV+ vs. HIV-  
No difference in LDL-FCR or LDL-RT in TN 
HIV+ vs. HIV- 
 
12 presumed 
uninfected (high 
HIV risk 
individuals 
required negative 
test within prior 3 
months) 
17 
Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
2005 
18 
Procedures done before 
and 8 weeks after ART 
inititiation:  
Standard diet, overnight 
fast, baseline blood 
sample, glucose infusion 
study(day 1), 1-13C 
Leucine infusion and 
1,1,2,3,3-2H5 glycerol 
injection over 12 hours 
with blood sampling 
~every 30 minutes for 3 
hours, then every 60 
minutes for 2 hours, then 
after 120, 180, 60 and 60 
minutes (day 2)   
 
Exclusions included: 
Drugs affecting glucose 
or lipoprotein 
metabolism, diabetes, 
lipid disorders, unstable 
weight 
13 treatment 
naïve (TN) males 
who subsequently 
started ARTs 
(regimens chosen 
independent of 
current study) 
HIV 
duration: not 
reported 
 
ART: 8 
weeks 
FFA, VLDL-apoB, 
VLDL-TG 
 
Fasting plasma 
VLDL-TG, VLDL-
c, VLDL-apoB, 
IDL-TG, IDL-c, 
IDL-apoB, HDL-
TG, HDL-c, HDL-
apoA1, glucose 
Lower plasma glucose levels in pre-ART vs. HIV- 
but no difference in plasma glucose in post-ART 
vs. HIV-. 
Higher plasma FFA (in response to glucose 
infusion) in both pre-ART and post-ART phase in 
HIV+ vs. HIV- 
Higher total plasma TG (in response to glucose 
infusion) in both pre-ART and post-ART phase in 
HIV+ vs. HIV- 
No difference in VLDL-apoB and VLDL-TG 
levels between TN HIV+ and HIV- 
Higher VLDL-apoB and VLDL-TG in treated 
HIV+ vs. HIV- 
Lower VLDL-apoB FCR (and clearance) and 
VLDL-TG FCR (and clearance) in TN HIV+ vs. 
HIV- 
Lower VLDL-apoB secretion rate and VLDL-TG 
secretion rate in TN HIV+ vs. HIV- but similar 
rates in treated HIV+ vs. HIV- 
14 healthy, 
younger, 
normolipemic 
subjects with 
similar BMI 
1999 
22* 
10-hour overnight fast, 
weight/height 
measurement, baseline 
blood sampling, 
continuous 2H5 
phenylalanine infusion 
for 6 hours, blood 
sampling every hour. 
5 males without 
secondary 
infections on 
ART 
 
5 healthy, 
uninfected (3 
male, 2 female) 
4±1 HDL-apoA-I Lower plasma concentration of HDL-apoA1 in 
HIV+ vs. HIV-  
Higher FSR of HDL-apoA1 in HIV+ vs. HIV- 
No difference in ASR of HDL-apoA1 in HIV+ vs. 
HIV- 
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Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
2003 
23* 
Standardized meal, 
baseline blood sampling, 
primed, intermittent 1-
13C leucine and 2H3-
leucine infusion for 4 
hours, blood sampling at 
5.25, 5.5, 5.75 hours 
from baseline 
5 infants (3 
males, 2 females) 
and 1 young male 
without 
secondary 
infection 
 
4 uninfected 
infants (1 male, 3 
females) born to 
HIV infected 
mothers from 
similar socio-
economic 
background as 
HIV+ 
~0.5-2.5 HDL-apoA-I Lower plasma concentration of HDL-apoA1 in 
HIV+ vs. HIV-  
Higher FSR of HDL-apoA1 in HIV+ vs. HIV- 
No difference in ASR of HDL-apoA1 in HIV+ vs. 
HIV- 
 
1992 
20 
Infection of CEM cell 
line with HTLVIII-b, 
quantitation of cellular 
lipids after 4 and 8 days 
CEM cells  Diacylglycerol 
(DAG), 
alkylacylglycerol 
(AAG), ceramide 
No difference in phospholipid concentration 
between infected and uninfected cells 
Small increase in DAG after 4 days 
Higher AAG (2.1 fold) and ceramide (2.8 fold) in 
infected vs. uninfected cells after 4 days 
Higher DAG (1.8-fold), AAG (2.6-fold) and 
ceramide (4.1-fold) in infected vs. uninfected cells 
after 8 days. 
 
19 
Year 
[Ref] 
Relevant study 
procedures 
Study groups 
HIV/ART 
Duration 
(years) 
Lipid(s)/ 
lipoprotein(s)/ 
measured 
Relevant result(s) 
21 Infection of ERIC cell 
line with HTLVIII-b, 
addition of radiolabelled 
lipid precursor (oleate), 
lipid kinetics after 4 days 
ERIC cells   Lower percentage uptake of radiolabelled tracer in 
infected vs. uninfected cells 
Lower counts per minute for radiolabelled tracer 
present in the following lipid classes in infected vs 
uninfected cells: phosphatidylcholine, 
phosphatidylinositol, phosphatidylethanolamine, 
phosphatidic acid, DAG. 
Higher counts per minute for radiolabelled tracer 
present in the following lipid classes in infected vs 
uninfected cells: triacylglycerol, cholesterol esters. 
 
*Despite the lack of ART-naïve subjects, these studies were included in this review as they were the only ones that met other criteria for AIM 1 
and examined HDL kinetics. 
HIV RNA, CD4 counts (cells/dl), HIV duration and ART duration presented as mean ± standard deviation. 
PI±: ART regimen including or not including a protease inhibitor 
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1.3.5 Effects of HIV infection on cellular lipids.  
Aim 2 was to describe how HIV-related changes in lipid/lipoprotein metabolism (in 
serum) altered the content and distribution of cellular lipids and lipoproteins. The results from 
Aim 2 may be better understood in the context of the dependence of HIV replication on host cell 
lipids 
24,25
 (reviewed in 
26,27
). However, it is important to remember that many of the alterations 
in lipid metabolism described in Aim1 are not specific to HIV infection 
1
. 
HIV entry and budding of new virions have been shown to occur preferentially at lipid-
enriched plasma membrane domains 
24,28-31
. Lipid rafts have been described as dynamic, highly-
ordered plasma membrane microdomains enriched in cholesterol, sphingolipids, and 
glycophosphatidylinositol-linked proteins 
29,32
 though their exact nature in vivo is debated 
33,34
. 
Postulated reasons for this site preference include the importance of cholesterol as a structural 
element in the viral envelope 
35
 and proximity-mediated activation of signaling proteins that 
occurs when these microdomains coalesce into larger domains 
27,36-38
.  
Specifically one structural hypothesis suggests that viral fusion to host cells may be 
optimized when the fluidity – determined by cholesterol and sphingolipid content – of the viral 
envelope is similar to that of the part of the host cell membrane where fusion occurs 
35
.  
The signaling hypothesis suggests that viral entry at lipid rafts simultaneously impairs the 
immune response to infection and alters signaling events promoting the spread of the virus to 
uninfected cells. For example, resting T-lymphocytes are made susceptible to HIV infection by 
stimulation through CD40 receptor binding 
39
 and lipid rafts are associated with CD40 clustering 
40
. 
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1.3.6 Effects of HIV-related alterations in lipid and lipoprotein metabolism on cellular 
lipid content and distribution.  
Given the potential importance of cellular lipids in viral replication, Aim 2 was to 
describe how serum lipids altered the content and distribution of cellular lipids and lipoproteins. 
We found 12 studies that met criteria for Aim 2. Most of these studies were performed in vitro or 
in animal models. 
The results from Aim 1 suggest increased triglyceride levels associated with HIV due to 
increased VLDL triglyceride content and reduced triglyceride clearance. Wang et al 
41
 reported 
that triglyceride–rich lipoproteins congregate (colocalize) with lipid rafts on endothelial cells. 
Triglyceride-rich lipoprotein lipolysis and colocalization of triglyceride-rich lipoprotein 
remnants was shown to cause aggregation of lipid rafts and movement of membrane components 
from raft to non-raft membrane regions.  
Results from Aim 1 also indicate an association between HIV infection and lower HDL-
cholesterol. Compared to people with low HDL-cholesterol, those with higher levels had higher 
cell membrane phospholipids and lower cholesterol to phospholipid ratios 
42
, which is less 
conducive to lipid raft formation. In fact, HDL has been shown to interact with and deplete lipid 
raft domains 
43
. The HDL receptor, SR-BI, however, is not strongly associated with lipid raft 
domains 
44
. Oxidized HDL interacting with macrophages decreases macrophage membrane 
fluidity, which was associated with decreased free cholesterol efflux from the macrophage 
45
. 
Compared to swine smooth muscle cells exposed to HDL, cells exposed to LDL had higher 
cholesterol to protein ratios, cholesterol to phospholipid ratios, and higher microviscosity (when 
cholesterol content of medium was ≥40 micrograms/ml) 46. 
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In Aim 1 we reported lower or similar LDL-cholesterol in HIV infected versus uninfected 
people. Prior work also suggests a reduction and subsequent increase in LDL-cholesterol 
following HIV seroconversion and ART initiation respectively 
47
. Lovastatin, an LDL-
cholesterol reducing agent 
48
 has been shown to reduce sterol synthesis and inhibit HIV 
replication 
31
. Incubation of endothelial cells with LDL in vitro resulted in increased cellular 
cholesterol content, increased cholesterol to phospholipid ratio, decreased cell membrane 
fluidity, and enhanced attachment of monocytes 
49
. Additionally, the surface area of lipid rafts on 
endothelial cells has been shown to decrease with exposure to oxidized LDL 
50
. Oxidized LDL 
induced the appearance of ceramide-enriched surface membrane microdomains on macrophage 
cell surfaces 
51
. Ceramide displaces cholesterol from lipid rafts 
52
, which may alter the 
composition and physical properties of the raft. Oxidized LDL also facilitates cholesterol efflux 
and disrupts the structure and order of cholesterol rich membrane domains in endothelial cells 
41,53
. 
1.4 DISCUSSION 
This review has linked several important concepts: 1) HIV infection alters serum/plasma 
lipid metabolism, 2) serum/plasma lipid alterations typically observed in HIV are associated with 
alterations in cellular lipids that may favor lipid raft formation, and 3) cellular lipid distribution, 
particularly lipid raft formation, may play an important role in multiple aspects of the HIV life 
cycle.  
The studies reviewed suggest that some features of HIV infection (for example increased 
triglyceride and decreased HDL concentrations, longer LDL residence times, decreased 
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phosphatidylcholine (a phospholipid) synthesis) may create conditions conducive to lipid raft 
formation. Given the dependence of HIV replication on these rafts, we propose that infection-
mediated alterations in lipid metabolism, intended as a beneficial pro-inflammatory immune 
process, may also create conditions that are more conducive to viral replication. Whether HIV 
actively “hijacks” this process or passively benefits from it is unclear and would be an interesting 
area for future study. This is particularly relevant to future HIV treatment given that studies in 
Aim 1 suggest an interaction between ART and HIV infection wherein ART exacerbates some of 
the lipid dysregulation observed in HIV 
16-18
. 
The associations between oxidized lipoproteins and lipid rafts raise interesting questions. 
Oxidized HDL was associated with decreased cholesterol efflux from plasma macrophage 
plasma membranes, while oxidized LDL was associated with decreased lipid raft area and 
cholesterol displacement from rafts. Whether HIV infection is associated with HDL oxidation is 
unclear. However, HIV infection may be associated with increased prevalence of oxidized LDL 
54
, possibly due to longer LDL residence times 
55
. While oxidized LDL may be detrimental to 
lipid raft maintenance – and consequently, HIV replication – the pro-inflammatory state 
associated with LDL oxidation may offset this by recruiting more HIV-susceptible immune cells 
into circulation. A reasonable hypothesis may suggest that HIV infection manipulates LDL-
oxidation and LDL metabolism to minimize the detrimental effects on lipid rafts while 
maximizing the immune activation associated with lipoprotein oxidation. 
As the principal site of cholesterol degradation, endogenous lipid metabolism, and acute 
phase protein synthesis, the liver is strongly implicated in infection-mediated changes in lipid 
metabolism. Whether and how HIV alters liver synthetic function, and whether altered hepatic 
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function provides net benefit to the host or virus over time are also important areas for future 
research. 
 
1.5 CONCLUSION 
In summary, we have described specific alterations in lipid and lipoprotein kinetics 
associated with HIV and how these alterations affect cellular lipids. Based on the dependence of 
successful HIV replication on host cellular lipids, we have proposed that HIV may “hijack” other 
components of the immune response (lipid dysregulation) in addition to “hijacking” T-
lymphocyte activation to amplify viral replication. 
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2.1 ABSTRACT 
Background: Biomarkers of inflammation, altered coagulation, and monocyte activation are 
associated with mortality and cardiovascular disease (CVD) in the general population and among 
human immunodeficiency virus infected people (HIV+). We compared biomarkers for 
inflammation, altered coagulation, and monocyte activation between HIV+ and uninfected 
people in the Veterans Aging Cohort Study (VACS). 
Methods: Biomarkers of inflammation (interleukin-6 (IL-6)), altered coagulation (D-dimer), and 
monocyte activation (soluble CD4 (sCD14)) were measured in blood samples from 1525 HIV+ 
and 843 uninfected VACS participants. Logistic regression was used to determine the association 
between HIV infection and prevalence of elevated (>75
th
 percentile) biomarkers adjusting for 
confounding comorbidities. 
Results: HIV+ Veterans had less prevalent CVD, hypertension, diabetes, obesity, hazardous 
drinking and renal disease, but more dyslipidemia, hepatitis C, and current smoking than 
uninfected Veterans. Compared to uninfected Veterans, HIV+ Veterans with HIV RNA ≥500 
copies/ml or CD4 count <200 cells/mm
3
 had a significantly higher prevalence of elevated IL-6 
(OR:1.54; 95% CI=1.14-2.09, OR:2.25; 95% CI:1.60-3.16 respectively) and D-dimer (OR:1.97; 
95% CI:1.44-2.71, OR:1.68; 95% CI:1.22-2.32 respectively) after adjusting for comorbidities. 
HIV+ Veterans with a CD4 cell count <200 cells/mm
3
 had significantly higher prevalence of 
elevated sCD14 compared to uninfected Veterans (OR:2.60; 95% CI:1.64-4.14). These 
associations still persisted after restricting the analysis to Veterans without known confounding 
comorbid conditions. 
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Conclusion: These data suggest that ongoing HIV replication and immune depletion 
significantly contribute to increased prevalence of elevated biomarkers of inflammation, altered 
coagulation, and monocyte activation. This contribution is independent of and in addition to the 
substantial contribution from comorbid conditions. 
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2.2 INTRODUCTION 
Untreated HIV infection and resulting immune depletion are associated with mortality 
and cardiovascular diseases (CVD) 
56
. Biomarkers of inflammation and altered coagulation are
associated with mortality and CVD within the general population 
57-60
 and among HIV infected
people 
61-64
. Further, soluble CD14 (sCD14), a biomarker of monocyte activation is linked with
increased mortality risk among HIV infected individuals 
65
and the general population 
66
. 
However, it is unknown whether inflammation, altered coagulation, and monocyte activation are 
primary mechanisms driving the association between HIV infection and mortality and CVD. 
Prior studies comparing HIV infected to uninfected individuals suggest that HIV 
infection is associated with inflammation, altered coagulation, and monocyte activation 
65,67-69
.
However, these studies were limited by the comparison of HIV infected and uninfected 
populations from different cohorts 
65,67,69
 and by their inability to consider degree of viral RNA
suppression, immune depletion 
68
, or comorbid conditions that also influence levels of these
biomarkers 
69
.  The latter limitation is particularly problematic in the study of HIV because those
with HIV likely have a greater burden of disease related to behaviors like smoking, alcohol, and 
drug use. Comparing HIV infected people to uninfected people who have a lower burden of non 
HIV-related disease makes it difficult to determine whether elevated biomarkers in those with 
HIV are driven by HIV infection or by the increased comorbidity burden among the HIV 
infected. 
The objective of this study was to investigate the effect of HIV status on biomarkers of 
inflammation, altered coagulation, and monocyte activation in the Veterans Aging Cohort Study 
(VACS). VACS contains detailed clinical data on HIV measures, substance use, and 
comorbidity, and an uninfected population with a comparable comorbidity burden. 
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2.3 METHODS 
2.3.1 Subject selection 
Subjects were selected from the VACS 
70
. Briefly, the VACS is an observational, 
prospective longitudinal study of HIV infected and age, race/ethnicity, sex, and site matched 
uninfected Veterans in care from eight United States Department of Veterans Affairs (VA) 
medical centers across the United States. In 2005-2006, the VACS collected and banked blood 
and DNA specimens on enrolled subjects from these sites. A total of 1,525 HIV infected and 843 
uninfected VACS participants consented to provide blood specimens for future studies. These 
specimens were collected using serum separator and EDTA blood collection tubes and shipped 
to a central repository at the Massachusetts Veterans Epidemiology Research and Information 
Center in Boston, Massachusetts. 
2.3.2 Independent variables 
HIV status was our primary independent variable. To understand the effects of poor viral 
suppression and immune depletion, we stratified HIV by viral RNA (uninfected, HIV infected 
with RNA <500 or ≥500 copies/mL) and by CD4 count (uninfected, HIV infected with CD4 
count <200, 200-499, or ≥500 cells/mm3). We further stratified these variables by antiretroviral 
therapy (ART) to understand the impact of ART among those with poor viral suppression or 
immune depletion. Current ART status was defined as taking ART within 90 days before or up 
to seven days after blood specimen collection.  
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2.3.3 Dependent variables 
Biomarkers of inflammation (interleukin 6 (IL-6)), altered coagulation (D-dimer), and 
monocyte activation (soluble CD14 (sCD14)) were our dependent variables (Laboratory for 
Clinical Biochemistry Research, University of Vermont). IL-6 was measured using a 
chemiluminescent immunoassay (QuantiGlo IL-6 immunoassay, R&D Systems, Minneapolis, 
MN). Calibration was done by the manufacturer and is traceable to National Institute for 
Biological Standards and Control 89/548 (IU/ml). Four levels of controls were run per sample, 
with the inter-assay coefficients of variability (CVs) ranging from 7.68% to 12.29%. D-dimer 
was measured using the STAR automated coagulation analyzer, (Diagnostica Stago) using an 
immuno-turbidometric assay (Liatest D-DI; Diagnostica Stago, Parsippany, NJ).  Four controls, 
with inter-assay CVs ranging from 2.77% to 14.78%, were used. The lab measured sCD14 with 
an ELISA (Quantikine sCD14 Immunoassay, R&D Systems Inc) with a detectable range of 40 – 
3200 ng/mL, using a standard 200-fold sample dilution. Again, four controls were used, with 
inter-assay CVs ranging from 7.19% to 8.11%. 
2.3.4 Covariates 
Sociodemographic data included age, sex, and race/ethnicity. We defined prevalent 
cardiovascular disease (CVD) as any of the following occurring prior to the date of blood 
specimen collection: 1) A myocardial infarction as defined by the VA Ischemic Heart Disease 
Quality Enhancement Research Initiative (IHD-QUERI) 
71
 or the Cardiovascular Health Study 
72
; 2) International Classification of Disease (ICD-9) or Current Procedural Terminology (CPT) 
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codes for congestive heart failure, coronary artery bypass graft, percutaneous coronary 
intervention, and ischemic stroke.  
Blood pressure was averaged over the three routine outpatient blood pressure 
measurements performed closest to the date of blood specimen collection. Hypertension was 
categorized based on Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure thresholds as no hypertension (blood pressure <120/80 mmHg 
and no documentation of antihypertensive medication); pre-hypertension (120-139/80-89 mmHg 
and no antihypertensive medication); controlled hypertension (<140/90 mmHg and 
documentation of antihypertensive medication); or uncontrolled hypertension (blood pressure 
≥140/90 mmHg) 73.  
Diabetes was diagnosed using glucose measurements, use of insulin or oral hypoglycemic 
agents, and/or ≥1 inpatient and/or 2 outpatient ICD-9 codes 74. Current, past, and never smoking 
and body mass index were determined from the VA Health Factors dataset 
75
.  
Cholesterol lowering medication use was assessed using patient pharmacy data. 
Cholesterol measurements (i.e., high-density lipoprotein (HDL); low-density lipoprotein (LDL) 
and serum triglycerides) were obtained from the VA Decision Support System (DSS). HDL was 
categorized as high, medium or low (≥60, 40-59, <40 mg/dL), LDL as optimal, near optimal, 
borderline high, or high/very high (<100, 100-129, 130-159, ≥160 mg/dL), and serum 
triglycerides as normal, borderline high, high/very high (<150, 150-199, ≥200 mg/dL) per 
National Cholesterol Education Program Adult Treatment Panel III criteria 
76
.  
Cocaine and alcohol use were determined by self-report. We categorized alcohol use with 
data from the Alcohol Use Disorders Identification Test (AUDIT-C) and alcohol abuse and 
dependence diagnoses using ICD-9 codes based on prior work in VACS 
77
: 1) current 
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infrequent/moderate drinking without alcohol abuse/dependence diagnosis, 2) current 
infrequent/moderate drinking with abuse/dependence diagnosis, 3) current hazardous drinking 
with or without abuse/dependence diagnosis, 4) past drinking. HCV virus (HCV) infection was 
defined as a positive HCV antibody test or at least 1 inpatient and/or 2 outpatient ICD-9 codes 
78
.
Renal disease was defined as an estimated glomerular filtration rate (eGFR) of less than 60 
mL/min/1.73m
2
 per National Kidney Foundation Kidney Disease Outcomes Quality Initiative
thresholds for chronic kidney disease 
79
.
 We collected data on HIV-1 RNA, CD4 count, and current antiretroviral therapy. We   
used CD4 counts and HIV-1 RNA measurements obtained as part of clinical care at the closest  
time point within 180 days before or after the date of the blood specimen collection. 
2.3.5 Statistical analyses 
Variables that were normally distributed, continuous but not normally distributed, or 
categorical were compared by HIV status using t tests, Wilcoxon rank sum tests, or χ2 tests
respectively. Mean age and race/ethnicity adjusted biomarker levels were compared by linear 
regression after transforming biomarker variables to approximate normality. Median biomarker 
levels were compared by comorbid disease status using Kruskall-Wallis tests. Spearman rank 
analysis with a Bonferroni correction for multiple comparisons was used to test correlations 
between biomarkers and continuous variables. 
We used multivariable logistic regression to estimate the association between HIV 
infection and prevalence of elevated (i.e., >75
th
 percentile) IL-6, D-dimer and sCD14. For each
biomarker, we assessed the association between the biomarker and 1) HIV status, 2) HIV 
stratified by RNA, 3) HIV stratified by CD4 count, and 4) HIV stratified by CD4 count or RNA, 
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and antiretroviral therapy (ART). Uninfected Veterans were the reference group for all HIV 
comparisons. All regression models were adjusted for 1) age, race/ethnicity and 2) age, 
race/ethnicity, prevalent CVD, hypertension, diabetes, smoking, BMI, cholesterol lowering 
medication use, HDL, LDL, triglycerides, cocaine use in the past year, alcohol use, HCV, and 
renal disease. We analyzed two-way interactions between HIV and each covariate and included 
significant interactions (p<0.05) in the final regression models.  
We also performed secondary analyses excluding comorbid conditions associated with 
our outcomes to better understand the independent effect of HIV infection on prevalence of 
elevated IL-6, D-dimer, and sCD14. Specifically, we excluded Veterans with confounding 
comorbid behaviors (current hazardous drinking or smoking) or diseases (CVD, uncontrolled 
hypertension, diabetes, BMI≥30 kg/m2, BMI<18 kg/m2, HCV, renal disease).  
To address missing covariate data, we used multiple imputation to generate 10 complete 
datasets to increase the robustness of estimated associations. Multiple imputation was done using 
the ICE command 
80
 (Stata v11.0 StataCorp).   
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2.4 RESULTS 
We collected 2,345 IL-6 measurements, 2,352 D-dimer measurements, and 2,357 sCD14 
measurements. Compared to uninfected Veterans, HIV infected Veterans were slightly younger 
(51.8 vs. 53.5 years; p<0.01), more likely to be male (97.3% vs. 90.4%), and had less prevalent 
CVD (6.3% vs. 12.8%), uncontrolled hypertension (24.3% vs. 28.7%), diabetes (19.5% vs. 
31.8%), BMI ≥30 kg/m2 (14.2% vs. 42.9%), cholesterol lowering medication use (26.9% vs. 
40.1%), current hazardous drinking (24.7% vs. 27.2%), and renal disease (8.1% vs. 10.2%) 
(p<0.05 for all; Table 3).  
HIV infected Veterans had more prevalent current smoking (50.6% vs. 47.3%), low HDL 
(44.8% vs. 33.6%), high/very high LDL (10.4% vs. 5.2%), high/very high triglycerides (22.7% 
vs. 12.0%), cocaine use in the past year (20.3% vs. 17.6%) and HCV (45.1% vs. 30.8%) (p<0.05 
for all; Table 3).  
Differences in median biomarker levels between infected and uninfected Veterans were 
most apparent when HIV was stratified by HIV-1 RNA or CD4 count (Figure 4). Median IL-6 
was greater in HIV infected compared to uninfected Veterans (2.08 vs. 1.79 pg/mL; p<0.01), 
while the reverse was true for median D-dimer (0.26 vs. 0.30 μg/mL; p<0.01). There was no 
difference between the two groups for median sCD14 (1.72 vs. 1.73 μg/mL; p=0.95) (Table 3). 
Median biomarker levels varied significantly by covariate and co-morbid disease status 
(Table 4) with many moderate but significant correlations (Table 5) between these measures. 
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Table 3. Baseline characteristics of study population 
 
HIV infected  
(N=1525) 
HIV uninfected  
(N=843) 
p-value 
Demographics (%)    
Age, years (mean ± SD) 51.8 ± 8.2 53.5 ± 9.3 <0.01 
Male 97.3 90.4 <0.01 
Race    0.69 
White 19.0 20.9  
African American 69.0 67.3  
Hispanic 8.3 7.8  
Other 3.8 4.0  
Cardiovascular disease risk factors (%)    
Prevalent cardiovascular disease  6.3 12.8 <0.01 
Blood pressure, mmHg    
Mean systolic (SD) 128.9 (14.4) 132.1 (14.6) <0.01 
Mean diastolic (SD) 78.7 (9.1) 78.8 (9.3) 0.82 
Hypertension   <0.01 
No hypertension 17.8 9.9  
Pre-hypertension 25.2 18.9  
Controlled hypertension 32.5 42.6  
Uncontrolled hypertension 24.3 28.7  
Diabetes 19.5 31.8 <0.01 
Smoking
 a
   <0.01 
Current 50.6 47.3  
Past 28.3 29.1  
Never 8.9 22.1  
BMI, kg/m
2 a    
Mean (SD) 25.5 (4.7) 29.5 (6.0) <0.01 
<18 2.0 0.6 
<0.01 
18-24.9 45.3 22.1 
25-29.9 36.5 33.1 
≥30 14.2 42.9 
Cholesterol lowering agent use 26.9 40.1 <0.01 
HDL cholesterol, mg/dL
 a
    
Median (mean ± SD) 41.0 (44.0±16.7) 44.5 (46.4±14.7) <0.01 
High (≥60) 11.2 10.6 
<0.01 Medium (40-59) 40.7 51.4 
Low (<40) 44.8 33.6 
LDL cholesterol, mg/dL
 a    
Median (mean ± SD) 
103.5 
(142.3±163.4) 
100.0 
(102.5±59.4) 
0.03 
Optimal (<100) 33.3 31.6 
<0.01 
Near optimal (100-129) 18.8 18.3 
Borderline high (130-159) 8.8 8.8 
High/Very high (≥160) 10.4 5.2 
Triglycerides, mg/dL
 a    
Median (mean ± SD) 
140.0 
(180.4±151.5) 
111.0 
(146.3±137.0) 
<0.01 
Normal (<150) 42.3 44.5 
<0.01 Borderline high (150-199) 13.2 9.1 
High/Very high (≥200) 22.7 12.0 
Other risk factors (%)    
Cocaine in past year (%) 20.3 17.6 0.03 
Hazardous drinking(%)
 a
   0.04 
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HIV infected  
(N=1525) 
HIV uninfected  
(N=843) 
p-value 
Current infrequent/moderate drinking 24.4 19.2  
Abuse/dependence; no current hazardous drinking 8.3 9.3  
Current hazardous drinking 24.7 27.2  
Past drinking 9.9 9.0  
Hepatitis C (%) 45.1 30.8 <0.01 
eGFR, mL/min/1.73m
2
    
Median (mean ± SD) 96.5 (98.8±33.0) 94.6 (97.8±43.2) 0.12 
<60 (%) 8.1 10.2 0.03 
Laboratory analysis    
CD4+ T lymphocyte count, cells/mm
3 a
     
Median (mean ± SD) 
392 (432.0 ± 
278.1) 
-- 
 
>= 500 (%) 33.4 --  
200-499.9 (% ) 43.8 --  
<200 (%) 20.4 --  
HIV-1 RNA, copies/mL 
a    
Median (mean ± SD) 
75 (20633 ± 
73540) 
-- 
 
<500 (%) 65.3 --  
>500 (%) 33.0 --  
Class of antiretroviral therapy (%)    
Protease inhibitors 45.7 --  
Non-nucleoside reverse transcriptase inhibitors 34.7 --  
Nucleoside analog reverse transcriptase inhibitors 76.7 --  
Biomarkers of inflammation, altered coagulation, monocyte 
activation 
   
IL-6,pg/ml median (mean ± SD) a 
2.08  
(3.36 ± 7.47) 
1.79  
(3.70 ± 14.82) 
<0.01 
>75th percentile IL-6 (%) 25.8 22.9 <0.01 
D-dimer, μg/ml median (mean ± SD) a 
0.26  
(0.50 ± 1.08) 
0.30  
(0.54 ± 0.93) 
<0.01 
>75th percentile D-dimer (%) 23.7 26.0 <0.01 
sCD14, μg/ml median (mean ± SD) a 
1.72  
(1.82 ± 0.55) 
1.73  
(1.81± 0.49) 
0.95 
>75th percentile sCD14 (%) 25.8 23.3 <0.01 
Abbreviations: HIV, human immunodeficiency virus; CVD, cardiovascular disease; BMI, body 
mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C 
virus; eGFR, estimated glomerular filtration rate; HIV-1, human immunodeficiency virus type-1. 
*For Smoking (N=1340 HIV+, 830 HIV-); BMI (N=1493 HIV+, 832 HIV-); HDL cholesterol 
(N=1173 HIV+, 590 HIV-); LDL cholesterol (N=1086 HIV+, 538 HIV-); Triglycerides (N=1191 
HIV+, 553 HIV-); cocaine (N=1468 HIV+, 795 HIV-); Hazardous drinker (N=1017 HIV+; 536 
HIV-); EGFR (N=1525 HIV+, 841 HIV-); CD4+ lymphocyte count (N=1488); HIV-1 RNA 
(N=1499); IL-6 (N=1521 HIV+, 824 HIV-); D-dimer (N=1523 HIV+, N=829 HIV-); sCD14 
(N=1525 HIV+; N=832 HIV-). 
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Figure 4: Distribution of age- and race/ethnicity-adjusted interleukin 6 (IL-6), D-dimer, and soluble CD14 
(sCD14) levels by human immunodeficiency virus (HIV) status, HIV-1 RNA level, and CD4 lymphocyte count  
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Table 4. Distributions of interleukin-6, D-dimer and soluble CD14 by HIV status and categorical covariates 
 
Median (mean±SD) 
IL-6 (pg/mL) D-dimer (μg/ml) sCD14 (μg/ml) 
Demographics    
Male 1.74 (2.59±2.51) 0.32 (0.46±0.77) 1.74 (1.77±0.45) 
Female 2 .00 (3.53±10.91) 0.28 (0.51±1.04) 1.72 (1.82±0.54) 
Race     
White 2.02 (3.04±4.18) 0.26 (0.42±0.55) 1.80* (1.90±0.50) 
African American 1.97 (3.48±11.14) 0.29 (0.55±1.19) 1.69* (1.79±0.54) 
Hispanic 2.17 (4.06±15.17) 0.26 (0.44±0.53) 1.75* (1.86±0.58) 
Other 2.04 (4.47±12.71) 0.29 (0.48±0.55) 1.74* (1.83±0.44) 
Cardiovascular disease risk factors   
No prevalent cardiovascular disease  1.95* (3.44±11.01) 0.26* (0.5±1.05) 1.72* (1.81±0.53) 
Prevalent cardiovascular disease  2.58* (3.9±5.35) 0.41* (0.68±0.78) 1.83* (1.93±0.56) 
Hypertension    
No hypertension 1.95* (3.32±7.19) 0.25* (0.5±1.28) 1.68* (1.78±0.55) 
Pre-hypertension 1.68* (2.47±3.63) 0.24* (0.42±1.01) 1.68* (1.75±0.48) 
Controlled hypertension 2.11* (3.78±10.12) 0.29* (0.5±0.63) 1.76* (1.88±0.54) 
Uncontrolled hypertension 2.1* (4.02±15.88) 0.32* (0.62±1.29) 1.73* (1.82±0.54) 
No diabetes 1.91* (3.18±6.25) 0.26* (0.49±1.02) 1.69* (1.79±0.52) 
Diabetes 2.22* (4.42±18.71) 0.34* (0.58±1.07) 1.81* (1.92±0.57) 
Smoking
 a
    
Current 2.1* (3.77±9.18) 0.29 (0.52±1.02) 1.77* (1.86±0.54) 
Past 2.00* (3.63±15.55) 0.29 (0.55±1.25) 1.71* (1.82±0.54) 
Never 1.66* (2.57±3.58) 0.28 (0.43±0.48) 1.64* (1.72±0.47) 
BMI, kg/m
2 a    
<18 2.36* (3.2±2.84) 0.37* (0.58±0.7) 1.84* (1.90±0.52) 
18-24.9 2.02* (3.75±10.00) 0.29* (0.56±1.31) 1.80* (1.92±0.57) 
25-29.9 1.79* (3.23±13.66) 0.26* (0.46±0.95) 1.67* (1.75±0.49) 
≥30 2.22* (3.49±6.5) 0.32* (0.51±0.58) 1.68* (1.76±0.50) 
No cholesterol lowering agent use 2.02 (3.3±6.2) 0.26* (0.51±1.12) 1.71 (1.81±0.53) 
Cholesterol lowering agent use 1.91 (4.03±18.57) 0.31* (0.51±0.68) 1.75 (1.84±0.55) 
HDL cholesterol, mg/dL
 a
    
High (≥60) 1.74* (2.58±2.74) 0.26* (0.44±0.55) 1.68* (1.79±0.57) 
Medium (40-59) 1.83* (3.74±16.32) 0.26* (0.49±1.21) 1.68* (1.78±0.53) 
Low (<40) 2.21* (3.45±6.19) 0.31* (0.58±1.24) 1.79* (1.88±0.56) 
LDL cholesterol, mg/dL
 a    
Optimal (<100) 2.14* (3.82±14.43) 0.29 (0.54±0.98) 1.75* (1.88±0.56) 
Near optimal (100-129) 1.82* (3.22±10.38) 0.26 (0.58±1.77) 1.72* (1.8±0.52) 
Borderline high (130-159) 1.96* (2.96±8.42) 0.28 (0.46±0.55) 1.66* (1.72±0.48) 
High/Very high (≥160) 1.96* (3.44±5.97) 0.29 (0.47±0.57) 1.72* (1.8±0.56) 
Triglycerides, mg/dL
 a    
Normal (<150) 1.91* (3.16±4.96) 0.28* (0.57±1.42) 1.68* (1.78±0.53) 
Borderline high (150-199) 2.1* (3.11±4.63) 0.29* (0.51±0.62) 1.71* (1.82±0.51) 
High/Very high (≥200) 2.16* (3.73±11.85) 0.26* (0.4±0.57) 1.82* (1.93±0.60) 
Other risk factors (%)    
No cocaine in past year 1.96 (3.56±11.96) 0.28 (0.48±0.79) 1.72 (1.81±0.53) 
Cocaine in past year  2.09 (3.24±4.46) 0.29 (0.61±1.44) 1.74 (1.85±0.53) 
Hazardous drinking(%) a    
Current infrequent/moderate drinking 1.70* (2.49+/-2.92) 0.25* (0.45+/-0.78) 1.67* (1.76+/-0.49) 
Abuse/dependence; no current hazardous 
drinking 2.08* (2.98+/-3.45) 
0.25* (0.45+/-0.52) 1.73* (1.85+/-0.53) 
Current hazardous drinking 2.09* (3.37+/-7.15) 0.29* (0.52+/-1.27) 1.73* (1.82+/-0.50) 
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Median (mean±SD) 
IL-6 (pg/mL) D-dimer (μg/ml) sCD14 (μg/ml) 
Past drinking 1.94* (5.21+/-26.02) 0.31* (0.58+/-1.40) 1.75* (1.87+/-0.56) 
No hepatitis C 1.81* (3.47±12.97) 0.28 (0.50±0.99) 1.67* (1.76±0.51) 
Hepatitis C 2.17* (3.5±5.59) 0.29 (0.53±1.09) 1.81* (1.91±0.55) 
eGFR≥60 1.95* (3.19±7.29) 0.26* (0.49±1.05) 1.70* (1.78±0.50) 
eGFR<60 2.63* (6.51±27.11) 0.46* (0.77±0.83) 2.08* (2.23±0.71) 
Abbreviations: HIV, human immunodeficiency virus; CVD, cardiovascular disease; BMI, body 
mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C 
virus; eGFR, estimated glomerular filtration rate; HIV-1, human immunodeficiency virus type-1. 
*p<0.05
a
For Smoking (N=1340 HIV+, 830 HIV-); BMI (N=1493 HIV+, 832 HIV-); HDL cholesterol
(N=1173 HIV+, 590 HIV-); LDL cholesterol (N=1086 HIV+, 538 HIV-); Triglycerides (N=1191 
HIV+, 553 HIV-); cocaine (N=1468 HIV+, 795 HIV-); Hazardous drinker (N=1017 HIV+; 536 
HIV-); EGFR (N=1525 HIV+, 841 HIV-); CD4+ lymphocyte count (N=1488); HIV-1 RNA 
(N=1499); IL-6 (N=1521 HIV+, 824 HIV-); D-dimer (N=1523 HIV+, N=829 HIV-); sCD14 
(N=1525 HIV+; N=832 HIV-). 
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Table 5: Correlations between biomarkers of inflammation, altered coagulation, immune activation HIV-related biomarkers and biomarkers of co-
comorbid disease 
IL6 D-dimer sCD14 
IL6 1.00 
D-dimer 0.37* 1.00 
sCD14 0.38* 0.22* 1.00 
Age 0.15* 0.16* 0.12* 
HIV-1 RNA 0.17* 0.25* 0.11* 
CD4+ T cell count -0.28* -0.21* -0.22* 
Systolic blood pressure 0.04 0.09* 0.01 
Diastolic blood pressure 0.02 0.02 0.01 
Body mass index 0.01 0.04 -0.14* 
High density lipoprotein cholesterol -0.15* -0.12* -0.11* 
Low density lipoprotein cholesterol -0.11* -0.06 -0.12* 
Triglycerides 0.09* -0.05 0.11* 
Estimated glomerular filtration rate -0.04 -0.06 -0.15* 
*p<0.05 for pairwise comparison with Bonferroni correction for multiple comparisons
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In age and race/ethnicity adjusted logistic regression models, HIV status was not 
associated with a higher prevalence of elevated IL-6 (OR:1.18; 95%CI=0.96-1.44), D-dimer 
(0.91; 0.74-1.11), or sCD14 (1.16; 0.95-1.42). After full covariate adjustment, the odds ratios 
(95% CI) for the association with IL-6, D-dimer, and sCD14 were 0.81 (0.55-1.19), 0.95 (0.75-
1.20) and 0.79 (0.62-1.02) respectively (Table 6). 
However, compared to uninfected Veterans, HIV infected Veterans with HIV-1 RNA 
≥500 copies/ml or CD4 count <200 cells/mm3 had a significantly higher prevalence of elevated
IL-6 (OR: 1.54; 95%CI=1.14-2.09, OR:2.25; 95%CI:1.60-3.16 respectively) and D-dimer (OR: 
1.97; 95%CI:1.44-2.71, OR:1.68; 95%CI: 1.22-2.32 respectively) after adjusting for confounders 
(Table 7). HIV infected Veterans with a CD4 cell count <200 cells/mm
3
 had significantly higher
prevalence of elevated sCD14 compared to uninfected Veterans (OR: 2.60; 95%CI:1.64-4.14; 
Table 7).  
In the adjusted HIV status model, the covariates age ≥60 years, current smoking, low 
HDL, current hazardous or past drinking were also associated with higher prevalence of elevated 
IL-6 (p<0.05 for all; Table 6). Age ≥70 years, black race/ethnicity, prevalent CVD, uncontrolled 
hypertension, low HDL, and renal disease were significantly associated with D-dimer (p<0.05 
for all; Table 6). High/very high triglycerides, HCV, and renal disease were significantly 
associated with sCD14 (p<0.05 for all; Table 6). These covariate associations were of 
comparable (or greater) magnitude to associations for the HIV variables. The magnitudes of the 
covariate associations were similar in the models stratified by HIV-1 RNA or CD4 cell count. 
HIV status had significant interactions with black race and renal disease (p<0.05 for both; 
Table 6). HIV-1 RNA had significant interactions with renal disease, diabetes and HCV (p<0.05 
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for all; Table 7). CD4 count had significant interactions with renal disease, current hazardous 
drinking and HCV (p<0.05 for all; Table 7). 
When we stratified HIV-1 RNA and CD4 counts by current ART status, only modest 
differences in the prevalence of elevated IL-6 and D-dimer between those on ART and not on 
ART were observed (Table 8).  
To assess the impact of HIV on elevated biomarker independent of confounding 
comorbidities, we excluded Veterans with prevalent comorbid behaviors or diseases (Table 9) 
that were associated with elevated biomarkers. Among these subsets of “healthier” Veterans, the 
magnitude of the association between HIV infection and prevalence of elevated biomarkers 
persisted and in some cases, was increased.   
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Table 6: The association between HIV infection and elevated (>75th percentile) biomarkers of inflammation 
(IL-6), altered coagulation (D-dimer) and monocyte activation (sCD14).  
 
IL-6 D-dimer sCD14 
 
OR 95% CI OR 95% CI OR 95% CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV infected 0.81 (0.55-1.19) 0.95 (0.75-1.20) 0.79 (0.62-1.02) 
Age <40, years 1.00 -- 1.00 -- 1.00 -- 
40-49 0.93 (0.57-1.52) 0.86 (0.53-1.40) 1.10 (0.67-1.82) 
50-59 1.36 (0.84-2.22) 1.28 (0.79-2.07) 1.24 (0.75-2.04) 
60-69 1.80 (1.05-3.08) 1.51 (0.88-2.57) 1.26 (0.72-2.20) 
≥70 2.15 (1.07-4.31) 2.23 (1.15-4.32) 1.30 (0.64-2.65) 
White race 1.00 -- 1.00 -- 1.00 -- 
African Americana 0.59 (0.40-0.88) 1.63 (1.22-2.18) 0.85 (0.65-1.11) 
Hispanic 1.22 (0.81-1.82) 1.29 (0.83-2.01) 0.98 (0.65-1.46) 
Other 0.73 (0.42-1.28) 1.21 (0.68-2.14) 0.76 (0.44-1.31) 
Prevalent CVD 1.39 (0.98-1.98) 1.89 (1.35-2.65) 1.17 (0.82-1.66) 
Normal BP, mmHg 1.00 -- 1.00 -- 1.00 -- 
Pre-hypertension 0.68 (0.48-0.96) 0.86 (0.60-1.22) 0.88 (0.63-1.23) 
Controlled hypertension 1.01 (0.73-1.40) 1.14 (0.82-1.58) 1.19 (0.86-1.64) 
Uncontrolled hypertension 1.21 (0.87-1.68) 1.44 (1.02-2.02) 0.91 (0.64-1.28) 
Diabetes 1.19 (0.93-1.54) 0.99 (0.77-1.28) 1.26 (0.98-1.62) 
Never smoker 1.00 -- 1.00 -- 1.00 -- 
Current 1.67 (1.17-2.37) 1.28 (0.92-1.79) 1.23 (0.88-1.73) 
Past 1.06 (0.74-1.53) 1.19 (0.83-1.72) 1.15 (0.81-1.63) 
BMI 18-25, kg/m
2
 1.00 -- 1.00 -- 1.00 -- 
<18 1.23 (0.58-2.60) 1.72 (0.83-3.58) 0.78 (0.35-1.73) 
25-29 0.85 (0.67-1.09) 0.72 (0.57-0.93) 0.55 (0.43-0.70) 
>30 1.33 (1.00-1.78) 0.98 (0.74-1.31) 0.43 (0.32-0.59) 
Cholesterol lowering medication   0.64 (0.50-0.83) 0.89 (0.69-1.14) 1.10 (0.86-1.41) 
High HDL (>60), mg/dL 1.00 -- 1.00 -- 1.00 -- 
Medium (40-59) 1.39 (0.98-1.98) 1.01 (0.72-1.41) 1.14 (0.78-1.65) 
Low (<40) 1.69 (1.16-2.48) 1.79 (1.25-2.56) 1.28 (0.88-1.87) 
Optimal LDL(<100), mg/dL 1.00 -- 1.00 -- 1.00 -- 
Near optimal (100-129) 0.88 (0.66-1.18) 0.77 (0.58-1.02) 0.91 (0.69-1.18) 
Borderline high (130-159) 0.84 (0.57-1.26) 1.23 (0.84-1.80) 0.86 (0.58-1.27) 
High or very high (≥160) 0.82 (0.57-1.19) 0.94 (0.65-1.36) 0.81 (0.59-1.11) 
Normal triglyceride(<150), mg/dL 1.00 -- 1.00 -- 1.00 -- 
Borderline high (150-199) 1.05 (0.76-1.44) 0.79 (0.56-1.11) 1.36 (1.00-1.84) 
High or very high (≥200) 0.90 (0.68-1.20) 0.74 (0.55-0.99) 1.60 (1.19-2.14) 
Cocaine use in last year 1.25 (0.94-1.65) 1.25 (0.94-1.65) 0.93 (0.70-1.23) 
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IL-6 D-dimer sCD14 
 
OR 95% CI OR 95% CI OR 95% CI 
Infrequent/Moderate drinking 1.00 -- 1.00 -- 1.00 -- 
Abuse/dependence; no current 
hazardous drinking 
1.24 (0.81-1.91) 0.94 (0.61-1.43) 1.20 (0.79-1.83) 
Current hazardous drinking 1.67 (1.22-2.29) 1.21 (0.88-1.67) 1.30 (0.95-1.77) 
Past drinking 1.94 (1.45-2.58) 1.25 (0.95-1.65) 1.19 (0.90-1.57) 
Hepatitis C 
 a 1.05 (0.84-1.32) 0.89 (0.71-1.13) 1.51 (1.20-1.89) 
eGFR<60 mL/min/1.73 m
2  a
 1.06 (0.61-1.86) 2.54 (1.84-3.48) 1.86 (1.11-3.11) 
IL-6 (N=2345); D-dimer (N=2352); sCD14 (N=2357) 
HIV, human immunodeficiency virus; CVD, cardiovascular disease; BMI, body mass index; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C virus; eGFR, 
estimated glomerular filtration rate. 
*Significant interactions with HIV infection: IL-6 (African American race and eGFR<60 
mL/min/1.73 m
2
); D-dimer (none); sCD14 (eGFR<60 mL/min/1.73 m
2
)  
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Table 7: The association between HIV infection stratified by a) HIV-1 RNA b) CD4 cell count and elevated 
(>75th percentile) biomarkers of inflammation (IL-6), altered coagulation (D-dimer), and monocyte 
activation (sCD14). 
a) IL-6 D-dimer sCD14 
i)  Age and race/ethnicity adjusted 
model 
OR 95% CI OR 95% CI OR 95%CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV infected; RNA <500 0.97 (0.77-1.21) 0.64 (0.51-0.81) 1.09 (0.88-1.35) 
HIV infected; RNA ≥500 1.69 (1.31-2.18) 1.61 (1.26-2.06) 1.40 (1.08-1.81) 
       
 IL-6 D-dimer sCD14 
ii) Fully adjusted model OR 95% CI OR 95% CI OR 95%CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV infected; RNA <500 1.04 (0.79-1.36) 0.71 (0.53-0.97) 0.89 (0.63-1.26) 
HIV infected; RNA ≥500 1.54 (1.14-2.09) 1.97 (1.44-2.71) 1.48 (1.00-2.20) 
 
b) IL-6 D-dimer sCD14 
i) Age and race/ethnicity adjusted 
model 
OR 95% CI OR 95% CI OR 95%CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV infected; CD4+ count ≥500 0.57 (0.42-0.76) 0.56 (0.42-0.74) 0.76 (0.58-1.01) 
HIV infected; CD4+ count 200-499 1.31 (1.04-1.66) 0.89 (0.70-1.14) 1.06 (0.83-1.35) 
HIV infected; CD4+ count <200 2.30 (1.73-3.06) 1.76 (1.33-2.34) 2.51 (1.89-3.32) 
       
 IL-6 D-dimer sCD14 
ii) Fully adjusted model OR 95% CI OR 95% CI OR 95%CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV infected; CD4+ count ≥500 0.58 (0.41-0.82) 0.61 (0.45-0.84) 1.04 (0.67-1.60) 
HIV infected; CD4+ count 200-499 1.41 (1.06-1.88) 0.97 (0.74-1.27) 1.25 (0.83-1.87) 
HIV infected; CD4+ count <200 2.25 (1.60-3.16) 1.68 (1.22-2.32) 2.60 (1.64-4.14) 
Models are adjusted for i) age and race/ethnicity ii) all covariates. 
Reference for all comparisons is HIV uninfected.  
HIV-1 RNA in copies/mL; CD4 count in cells/mm
3
 
a) IL-6 (N=2319); D-dimer (N=2326); sCD14 (N=2331) 
Significant interactions in fully adjusted model: IL-6 (HIV-1 RNA < or ≥500 and eGFR<60 
mL/min/1.73 m
2
; p<0.05), D-dimer (HIV-1 RNA≥500 and diabetes; p<0.05), sCD14 (HIV-1 
RNA < or ≥500 and HCV, HIV-1 RNA<500 and eGFR<60 mL/min/1.73 m2; p≤0.05 for all) 
Abbreviations: OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration 
rate; HCV, hepatitis C virus. 
b) IL-6 (N=2308); D-dimer (N=2315); sCD14 (N=2320) 
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Significant interactions in fully adjusted model: IL-6 (CD4≥200 and eGFR<60 mL/min/1.73 m2; 
p≤0.05), sCD14 (CD4≥200 and current hazardous drinking, any CD4 count and hepatitis C; 
p<0.05 for all) 
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Table 8: The association between HIV infection and elevated (>75%) biomarkers of inflammation (IL-6), 
altered coagulation (D-dimer), and monocyte activation (sCD14). 
a) IL-6 D-dimer sCD14 
OR 95% CI OR 95% CI OR 95% CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
HIV-1 RNA <500; ART- 0.82 (0.47-1.42) 0.58 (0.33-1.03) 0.57 (0.33-0.99) 
HIV-1 RNA <500; ART+ 1.19 (0.92-1.55) 0.71 (0.54-0.92) 0.87 (0.67-1.12) 
HIV-1 RNA ≥500; ART- 1.40 (0.97-2.02) 1.54 (1.08-2.19) 0.62 (0.42-0.93) 
HIV-1 RNA ≥500; ART+ 2.04 (1.45-2.88) 1.62 (1.15-2.27) 1.54 (1.10-2.15) 
b) IL-6 D-dimer sCD14 
OR 95% CI OR 95% CI OR 95% CI 
HIV uninfected 1.00 -- 1.00 -- 1.00 -- 
CD4≥200; ART- 0.95 (0.66-1.38) 1.03 (0.73-1.47) 0.37 (0.24-0.57) 
CD4≥200; ART+ 1.16 (0.89-1.50) 0.73 (0.56-0.95) 0.82 (0.63-1.06) 
CD4<200; ART- 2.73 (1.60-4.65) 1.85 (1.08-3.18) 1.96 (1.14-3.36) 
CD4<200; ART+ 2.31 (1.62-3.27) 1.60 (1.12-2.26) 1.82 (1.29-2.56) 
Models stratified by a) HIV-1 RNA (copies/mL) b) CD4 lymphocyte count (cells/mm
3
) and use
of antiretroviral therapy (ART) and adjusted for all covariates. 
a) IL-6 (N=2319); D-dimer (N=2326); sCD14 (N=2331).
b) IL-6 (N = 2308); D-dimer (N = 2315); sCD14 (N = 2320).
OR, odds ratio; CI, confidence interval; HIV-1, human immunodeficiency virus type-1; ART, 
antiretroviral therapy. 
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Table 9: Effect of excluding Veterans with selected comorbid behaviors and diseases on the association between HIV infection and prevalence of 
elevated biomarkers of inflammation (IL-6), altered coagulation (D-dimer), and monocyte activation (sCD14). 
Biomarker Comorbidities 
Omitted 
Adjusted odds ratios 
(95% CI) 
Reference Model 1 Model 2 Model 3 
HIV 
uninfected 
HIV 
infected 
HIV 
RNA 
<500 
HIV 
RNA 
≥500 
CD4 
count 
≥500 
CD4 
count 
200-499 
CD4 
count 
<200 
IL-6 
None 
1.00 0.81 1.04 1.54 0.58 1.41 2.25 
-- (0.55-1.19) (0.79-1.36) (1.14-2.09) (0.41-0.82) (1.06-1.88) (1.60-3.16) 
Behaviors 
1.00 1.39 1.24 1.84 0.73 1.61 
2.82 
-- (0.91-2.12) (0.79-1.94) (1.03-3.27) (0.41-1.28) (0.98-2.64) (1.53-5.19) 
Diseases 
1.00 1.36 0.92 2.37 0.64 1.26 3.95 
-- (0.77-2.39) (0.49-1.73) (1.23-4.57) (0.29-1.41) (0.65-2.44) (1.91-8.2) 
D-dimer 
None 
1.00 0.95 0.71 1.97 0.61 0.97 1.68 
-- (0.75-1.20) (0.53-0.97) (1.44-2.71) (0.45-0.84) (0.74-1.27) (1.22-2.32) 
Behaviors 
1.00 0.71 0.56 1.27 0.49 0.75 1.21 
-- (0.48-1.05) (0.36-0.85) (0.75-2.17) (0.29-0.82) (0.47-1.22) (0.66-2.25) 
Diseases 
1.00 1.33 0.67 3.04 0.60 1.14 3.67 
-- (0.76-2.32) (0.35-1.26) (1.61-5.74) (0.28-1.30) (0.60-2.18) (1.82-7.38) 
sCD14 
None 
1.00 0.79 0.89 1.48 1.04 1.25 2.60 
-- (0.62-1.02) (0.63-1.26) (1.00-2.20) (0.67-1.60) (0.83-1.87) (1.64-4.14) 
Behaviors 
1.00 1.39 1.23 2.08 1.17 1.28 2.43 
-- (0.91-2.14) (0.79-1.92) (1.17-3.72) (0.7-1.94) (0.78-2.12) (1.32-4.49) 
Diseases 
1.00 0.92 0.72 1.51 0.76 0.67 2.36 
-- (0.56-1.52) (0.42-1.24) (0.83-2.75) (0.41-1.42) (0.36-1.22) (1.21-4.58) 
Models stratified by a) HIV status b) HIV-1 RNA and c) CD4 count and adjusted for all covariates  
Reference for all models is HIV uninfected 
Independent variables: Model 1 (HIV status); Model 2 (HIV status stratified by HIV-1 RNA (copies/mL)) Model; 3 (HIV status 
stratified by CD4 lymphocyte count (cells/mm
3
))
Covariates: All models were adjusted for the following covariates excluding the comorbidities omitted: Age, race/ethnicity, prevalent 
CVD, hypertension, diabetes, smoking, BMI, cholesterol lowering medication use, HDL, LDL, triglycerides, cocaine use in the past 
year, hazardous drinking, hepatitis C, and renal disease 
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Comorbid behaviors omitted: current smoking, current hazardous alcohol drinking. Regression sample size ranges from 891 to 908 
due to covariate variation between imputed datasets and missingness of outcomes and independent variables. 
Comorbid diseases omitted: CVD, uncontrolled hypertension, diabetes, BMI≥30 kg/m2, BMI<18 kg/m2, HCV, renal disease.
Regression sample size ranges from 574 to 587 due to covariate variation between imputed datasets and missingness of outcomes and 
independent variables. 
OR, odds ratio; CI, confidence interval; HIV-1, human immunodeficiency virus type-1; CVD, cardiovascular disease; BMI, body 
mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C virus; eGFR, estimated glomerular 
filtration rate.
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2.5 DISCUSSION 
Compared to uninfected Veterans, infected Veterans with HIV-1 RNA ≥500 
copies/mL had a higher prevalence of elevated IL-6 and D-dimer. HIV infected Veterans 
with CD4 counts <200 cells/mm
3
 had a higher prevalence of elevated IL-6, D-dimer, and 
sCD14 compared to uninfected Veterans. Importantly, the increased prevalence of these 
elevated biomarkers among HIV infected Veterans occurred despite the fact that the 
uninfected Veterans had similar or higher prevalence of comorbid conditions that were 
also strongly and significantly associated with prevalence of elevated biomarkers.  
Our data confirm that comorbid conditions like CVD, and renal disease are 
important contributors to the prevalence of elevated biomarkers. However, excluding 
Veterans with confounding comorbid behaviors or diseases did not diminish the 
associations between HIV and increased prevalence of elevated biomarkers. The 
magnitude of some associations actually increased among Veterans with high viremia or 
immune depletion. Together, these findings point to the importance of addressing both 
HIV- and non HIV-related morbidity in clinical practice to potentially minimize 
elevations in these biomarkers that are associated with mortality and cardiovascular 
disease.   
Our findings are consistent with prior studies demonstrating a significant 
association between HIV infection and elevated IL-6 and D-dimer. Neuhaus et al 
67
 
showed IL-6 and D-dimer levels were respectively 152% and 94% higher among HIV 
infected individuals in the Strategies for Management of Antiretroviral Therapy 
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(SMART) study compared to levels in uninfected individuals of similar age in the Multi 
Ethnic Study of Atherosclerosis (MESA) (p<0.001 for both). Our study of Veterans 
found age and race/ethnicity adjusted IL-6 and D-dimer levels were 18% higher and 
lower respectively in infected Veterans. The smaller difference in these biomarkers in the 
VACS may be explained by the fact that our uninfected Veterans came from the same 
healthcare clinics as our HIV infected Veterans, and thus had a more comparable burden 
of comorbid disease. For example, smoking and dyslipidemia were less prevalent among 
uninfected Veterans, but they had a higher burden of CVD obesity, and diabetes. In 
contrast Neuhaus et al 
67
 reported that uninfected participants in MESA had a lower 
prevalence of CVD, diabetes, and smoking as compared to HIV infected participants in 
the SMART study. Selecting population based controls or participants from established 
cohort studies could result in a relatively “healthier” uninfected referent group. Because 
comorbidities like CVD risk factors are associated with elevated biomarkers of 
inflammation 
81-83
, altered coagulation 
84-86
, and/or monocyte activation 
87,88
, the effects 
of HIV on these biomarkers in HIV infected Veterans may have been balanced partially 
by the effects of these comorbidities among uninfected Veterans in the VACS. 
Our results are also consistent with findings by Kuller et al 
61
 demonstrating that 
higher levels of IL-6 and D-dimer occurred in participants randomized to the SMART 
study drug conservation arm (intermittent ART), compared to those in the viral 
suppression arm (ongoing ART). In our study, unsuppressed HIV-1 RNA and low CD4 
counts were each associated with a significantly higher prevalence of elevated IL-6 and 
D-dimer. It should be noted that our reference group (uninfected individuals) was 
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different from the reference group in SMART (virally suppressed HIV infected 
individuals).  
Prior studies in HIV infected and uninfected people reported higher biomarkers of 
monocyte activation among those infected with HIV 
69,89,90
. Our results suggest that this 
phenomenon is specific to those with low CD4 counts as there was no difference in the 
prevalence of elevated sCD14 by HIV status unless the CD4 count was <200 cells/mm
3
. 
Although sCD14 is a biomarker of monocyte activation rather than a specific biomarker 
for microbial translocation, this finding among immune depleted Veterans is consistent 
with prior work demonstrating that microbial translocation is associated with chronic 
HIV infection and substantial CD4 cell depletion in the gastrointestinal tract 
91-93
. 
Differences between our study and prior reports may partially be explained by their 
smaller sample sizes, restricted generalizability, and the greater comorbid disease burden 
among their infected versus uninfected participants. Our lack of a significant difference 
in sCD14 between infected Veterans with a CD4 count ≥200 cells/mm3 and uninfected 
Veterans may be partially explained by the relatively balanced number of stimulators for 
immune activation between the two groups; infected Veterans had a higher prevalence of 
HCV while uninfected Veterans had a higher prevalence of obesity and diabetes, with 
current hazardous drinking being fairly similar between the two groups (Table 1).  
Strengths of our study include a large cohort providing excellent power to detect 
clinically important differences between HIV infected and uninfected participants. The 
cohort also contains important subgroups – particularly Blacks, and people with HCV 
and/or substance use disorders. Our uninfected Veterans have a comparable burden of 
comorbid conditions to infected Veterans. We know this because we have detailed data 
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on important comorbidities such as prevalent CVD, diabetes, blood pressure values, lipid 
levels, smoking data and pharmacy refill data on antiretroviral therapy.  
There are limitations that warrant discussion. First, the cross-sectional study 
design does not allow us to determine cause and effect. Second, the time window 
between ART ascertainment and blood specimen collection may have resulted in some 
misclassification by ART status. Third, it is likely that each biomarker is neither unique 
to, nor does it completely describe the complex biologic process of inflammation, altered 
coagulation or monocyte activation. The inclusion of lipopolysaccharide and 16S rDNA 
in combination with sCD14 may provide more accurate insights into the microbial 
translocation process. Fourth, this study also lacked biomarkers of immune activation 
(e.g. TNF alpha, IL-1 beta, IL-10). Such biomarkers would be valuable for providing 
insights into the immune response to the inflammatory processes studied. Finally, as our 
cohort is overwhelmingly male, our results may not be generalizable to women.   
2.6 CONCLUSION 
In conclusion, HIV infected Veterans with unsuppressed HIV viremia or a low 
CD4 count had a significantly higher prevalence of elevated IL-6 and D-dimer as 
compared to uninfected Veterans. This was true despite the fact that uninfected Veterans 
had a similar or higher burden of comorbid diseases that were associated with elevations 
in these biomarkers. Increased monocyte activation as measured by sCD14 only differed 
by HIV status when infected Veterans had CD4 counts <200 cell/mm
3
. These data 
suggest that both ongoing HIV replication and immune depletion and comorbid 
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conditions like CVD and renal disease, contribute to elevated biomarkers associated with 
inflammation, altered coagulation, and monocyte activation. Focusing on viremia 
reduction, CD4 cell restoration and treatment of non-HIV related comorbidity may be an 
important strategy to reduce mortality and CVD risk.  
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3.1 ABSTRACT 
 
 
 
 
Background: Assessing whether hepatitis C (HCV) co-infection with human 
immunodeficiency virus (HIV) is associated with increased inflammation is complex. 
The liver, integral to inflammatory biomarker synthesis, is compromised by HCV and 
alcohol abuse. Using single liver-synthesized biomarkers (e.g. C-reactive protein) to 
represent inflammation may not be appropriate in HIV/HCV co-infection. We 
hypothesized that 1) detectable HIV/HCV RNA was independently associated with 
increased inflammation; 2) a composite inflammation measure describes inflammation 
differently from single inflammatory biomarkers. 
Methods: We compared inflammation by HIV/HCV group in a cohort of 361 HIV 
infected participants from the HIV-Longitudinal Interrelationships of Viruses and 
Ethanol study. Inflammatory biomarkers >75th percentile were considered elevated. 
Associations between HIV/HCV group and elevated biomarkers were analyzed as a 
composite measure (inflammatory burden) or individually. We defined inflammatory 
burden as number of concurrently elevated biomarkers. Biomarkers included interleukin- 
6 (IL-6), C-reactive protein (CRP), cystatin C, serum amyloid-A (SAA), tumor necrosis 
factor-alpha (TNF-α), interleukin-10 (IL-10). Covariates: alcohol, liver fibrosis, 
comorbidities, CD4 count, antiretroviral therapy, substance use. 
Results: Detectable HIV and HCV RNA (OR=2.49; 95%CI=1.05–5.89) and detectable 
HCV RNA alone (2.95; 1.08–8.01) were independently associated with increased odds of 
having a greater inflammatory burden compared to undetectable viremia. Elevated IL-10 
(7.79; 1.90–31.97) and TNF-α (7.70; 1.42–41.83) were independently associated with 
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detectable HIV and HCV RNA. Elevated IL-10 was also associated with detectable HCV 
RNA alone (5.51; 1.17, 25.84). 
Conclusion: Detectable HIV and HCV replication versus undetectable replication was 
associated with inflammatory burden and certain inflammatory biomarkers independently 
of alcohol consumption, liver fibrosis and other comorbidities. 
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3.2 INTRODUCTION 
 
 
 
 
 
 
Several reports suggest that human immunodeficiency virus (HIV) infection and 
hepatitis C (HCV) co-infection with HIV are associated with increased cardiovascular 
disease (CVD) risk 94-97. Prior studies also link chronic inflammation, monocyte 
activation and/or altered coagulation with acute myocardial infarction and death in HIV 
infected people 61,62,65,98. Whether HIV and HCV mediate their effects on CVD risk 
through these mechanisms is not known. Assessing whether HIV mono- and HIV/HCV 
co-infection are associated with increased inflammation is therefore important, though 
not straightforward. Liver damage caused by alcohol consumption and HCV may alter 
serum levels of inflammatory biomarkers that are synthesized in the liver (e.g., C reactive 
protein) and possibly confound the association between viremia and biomarkers of 
systemic inflammation. Moreover, using a single biomarker, particularly one synthesized 
in the liver, to represent systemic levels of inflammation may not adequately represent 
this complex process. Whether a composite measure involving multiple elevated 
inflammatory biomarkers, including those synthesized in the liver, provides a more 
complete representation of the state of inflammation in the setting of HIV/HCV infection 
is not clear. 
The objective of this study, therefore, was to examine the association between 
HIV and HCV viremia and biomarkers of inflammation while accounting for alcohol 
consumption and liver fibrosis. 
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3.3 METHODS 
 
 
 
3.3.1 Study sample 
 
 
 
 
Baseline data were collected from 361 HIV infected participants in the HIV- 
Longitudinal Interrelationships of Viruses and Ethanol (HIV-LIVE) study. HIV-LIVE is 
a prospective cohort of HIV infected people with current or past alcohol problems. As 
previously reported 99, 400 HIV-LIVE participants were enrolled from four different 
sources from August 2001 to July 2003: (1) an existing cohort of HIV-infected 
participants with alcohol problems; (2) Boston Medical Center (BMC)’s Diagnostic 
Evaluation Unit; (3) Beth Israel Deaconess Medical Center (BIDMC) primary care and 
specialty clinics; and (4) local health care sites or shelters in the Boston area. Participants 
were included if they had a positive HIV antibody test (ELISA, confirmed by Western 
blot), had two or more affirmative responses to the CAGE (Cut down, Annoyed, Guilty, 
and Eye opener) alcohol screening questionnaire 100 or by physician-investigator 
diagnosis of alcoholism, spoke English or Spanish, and had at least one contact person 
likely to know the participant’s whereabouts. Individuals were excluded if the 30-item 
Folstein Mini-Mental State Examination score 101 was less than 21 or a trained 
interviewer deemed the patient incapable of comprehending the informed consent or 
answering interview questions. 
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3.3.2 Ethics statement 
The Institutional Review Boards of Boston Medical Center, Beth Israel 
Deaconess Medical Center, and the University of Pittsburgh approved this study. 
3.3.3 Dependent variable 
We defined an elevated biomarker as a serum biomarker level >75th percentile 
based on prior studies 61,102. We examined the following seven biomarkers: interleukin-6 
(IL-6), C-reactive protein (CRP), cystatin C, serum amyloid A (SAA), tumor necrosis 
factor-alpha (TNF-α), monocyte chemotactic protein-1 (MCP-1), and interferon gamma 
(IFN-γ). The primary outcome, inflammatory burden score, was defined as the presence 
of zero, one, two, or three or more elevated biomarkers. For example, an inflammatory 
burden score of 0 corresponds to having none of the seven biomarkers elevated. We 
defined a score of 3 as having at least three of the seven biomarkers elevated since few 
people had between four and seven biomarkers elevated. Our secondary outcomes were 
elevated individual inflammatory biomarkers and included interleukin-10 (IL-10). 
Importantly, IL-10 was not included in the inflammatory burden score because of its anti- 
inflammatory properties. For both outcomes, these biomarkers were chosen due to their 
associations with cardiovascular morbidity and mortality 60,103-105, HIV 61,67,106, or their 
synthesis in the liver 107,108. 
IL-6 was measured by ELISA (Quantiglo Human IL-6 Immunoassay; R&D 
Systems, Minneapolis, MN) with an assay range of 0.48–1500 pg/mL. The intra-assay 
and inter-assay coefficients of variation (CVs) ranged from 3.0–5.8% and 6.3–9.6%, 
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respectively. CRP, cystatin C and SAA were measured using a particle enhanced 
immunonepholometric assay (BNII nephelometer; Dade Behring Inc., Deerfield, IL). The 
CRP assay range was 0.16–1100 ug/mL. Intra-assay CVs ranged from 2.3–4.4% and 
inter-assay CVs ranged from 2.1–5.7%. The cystatin C assay range was 0.195–7.330 
mg/L. Intra- and inter-assay CVs were <5%. The SAA assay range and minimum 
detectable level were determined by the lower limit of the reference curve and were 
dependent on the concentration of the SAA standard used in the assay (N SAA Standard 
SY). Intra-assay CVs ranged from 4.3–6.2% and inter-assay CVs ranged from 2.8–4.7%. 
TNF-α, MCP-1, IL-10 and INF-γ were measured using the Human Serum Adipokine 
Panel B LINCOplex Kit (Linco Research, Inc. St. Charles, MO). The TNF-α and MCP-1 
assay ranges were 3.2–50,000 pg/mL. Intra- and inter-assay CVs ranged from 1.4-7.9% 
and < 21%, respectively. The IL-10 assay range was 3.2–10,000 pg/mL. Intra- and inter- 
assay CVs ranged from 4.8–9.0% and 3.1–18.4%, respectively. For INF-γ, the assay 
range was 3.2–10,000 pg/mL. Intra- and inter-assay CVs ranged from 4.8–9.0% and 3.1– 
18.4%, respectively. All assays were performed at the Laboratory for Clinical 
Biochemistry Research (University of Vermont, Burlington, VT). 
3.3.4 Independent variable 
Detectable viremia was the independent variable categorized into one of four 
groups: HIV and HCV RNA undetectable (undetectable), HIV RNA but not HCV RNA 
detectable (HIV mono-detectable), HIV RNA undetectable but HCV RNA detectable 
(HCV mono-detectable), and HIV and HCV RNA detectable (HIV/HCV detectable). The 
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undetectable group was the referent group for all analyses. HCV RNA was determined 
from serum collected at the time of enrollment or from participants’ medical records. All 
participants were HIV antibody positive. HIV RNA testing was performed using a 
branched-chain DNA assay or polymerase chain reaction (PCR) 109. The lower threshold 
of detection was 50-75 copies/mL. All subjects were tested for HCV infection by 
measuring HCV antibodies and antibody-positive subjects were tested for HCV RNA if 
this was unavailable from medical records. HCV RNA was measured either by branched 
chain DNA or PCR-based assays. The lower level of detection of the assays was 615 
IU/mL. HCV antibody-negative subjects were assumed to be HCV RNA negative 110. 
3.3.5 Covariates 
Demographic covariates were age; gender; race (white vs. non-white). Liver 
fibrosis was assessed as a fibrosis index-4 (FIB-4) score ≥1.45 111. We detailed alcohol 
use data using the 30-day TimeLine Follow Back instrument 112. Current at-risk alcohol 
consumption  was  defined  per  National  Institute  on  Alcohol  Abuse  and  Alcoholism 
criteria: drinking >14 standard drinks for men (>seven for women) per week or >four 
drinks on one occasion for men (>three drinks for women) in the last 30 days 113. Other 
covariates were CD4+ T-cell count <200 cells/mm3 and self-reported antiretroviral 
therapy (ART) use at time of assessment, and obesity (body mass index (BMI) ≥30 
kg/m2). Self-reported comorbid disease was defined as a “yes” response to any of the 
following questions: “Has a doctor ever told you that you had: CVD (peripheral vascular 
disease, hardening of the arteries in your neck or legs, atherosclerosis; a stroke, 
cerebrovascular accident, blood clot or bleeding in the brain, or transient ischemic attack; 
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or a heart attack or myocardial infarction); diabetes or high blood sugar or sugar; 
hypertension or high blood pressure; high cholesterol; renal disease (poor kidney function 
or blood tests showing high creatinine); or anemia (low red blood cell count, 
hemoglobin)?” 
For other substance use variables, we defined current smoking as a “yes” response 
to the question, “Do you currently smoke cigarettes every day or on  some  days?”; 
cocaine use as self-reported use of “cocaine, crack or free base”; and injection drug use as 
a “yes” response to the question, “In your lifetime, have you ever injected drugs?” 
3.3.6 Analysis 
Baseline characteristics and biomarker distributions were described and compared 
by HIV/HCV group using ANOVA, Kruskal Wallis tests, or chi-square tests as 
appropriate. Biomarker distributions were also described and compared by covariates. 
The primary analysis (labeled A) used a proportional odds model to estimate the 
odds of more elevated (>75th percentile) biomarkers. Two models were fit: (1) an 
unadjusted model with HIV/HCV status only; (2) an adjusted model with HIV/HCV 
status, age, gender, FIB-4 score, at-risk drinking, CD4 count, ART use, and self-reported 
comorbidity. The proportional odds model estimates the proportional odds (Podds) of 
having more than N concurrently elevated biomarkers versus N or fewer. For example, 
compared to those in the undetectable group, the odds of having more than two versus 
two or fewer elevated biomarkers is Podds  greater for those in the HIV/HCV detectable 
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group. The assumption of proportional odds implies that the coefficients that describe the 
relationship between an inflammatory burden score of 0 compared to a score of 1 or more 
are the same as those for an inflammatory burden score of 1 compared to 2 or more. This 
assumption was assessed by the Score Test. Our secondary analyses used logistic 
regression to model the odds of having an elevated individual biomarker (labeled B-I) 
adjusted for the covariates in the models above. Spearman correlation was used to assess 
potential collinearity in the regression models. No pair of variables within a regression 
model was highly correlated (r>0.40). Analyses were conducted using two-sided tests and 
a significance level of 0.05 and performed using SAS 9.3 (Cary, NC). 
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Table 10: Sources, targets and effects of biomarkers investigated in this study. 
Biomarker Secreted by Targets and effects 
IL-6 Macrophages, endothelial cells 
Liver (induces acute phase proteins); 
influences adaptive immunity 
(proliferation and antibody secretion of B 
cell linkage) 
CRP Hepatocytes 
Activates complement, deposits an 
opsonin on surface of microorganisms to 
facilitate phagocytosis 
Cystatin C All nucleated cells 
Inhibits cysteine proteinases from 
breaking down proteins. Cleared by 
glomerular filtration so used as a marker 
of renal disease. Correlated with 
inflammatory biomarkers (IL-6, CRP, 
TNF-α in MESA). 
SAA Hepatocytes, adipocytes 
During acute phase reaction, liver is major 
site of SAA synthesis, but in non-acute 
conditions, adipocytes secrete SAA. SAA 
is expressed in response to pro- 
inflammatory cytokines and associates 
with HDL particles to alter reverse 
cholesterol transport. 
TNF-alpha 
Monocytes, 
macrophages, other 
(activated T cells, 
NK cells, 
neutrophils, 
fibroblasts) 
Vasculature (inflammation); liver 
(induction of acute phase proteins); loss of 
muscle, body fat (cachexia); induction of 
death in many cell types; neutrophil 
activation 
MCP-1 Hepatic stellate cells61 
Cytokine that recruits monocytes, memory 
T cells, and dendritic cells to the sites of 
inflammation produced by either tissue 
injury or infection. 
IL-10 
Activated subsets of 
CD4+ and CD8+ T 
cells (TH2 cells) 
Stimulates or enhances B-cell proliferation 
(as well as thymocytes, mast cells); IgA 
synthesis and secretion by B-cells; 
antagonizes generation of TH1 cells. 
IFN-gamma TH1 cells, CD8
+ 
cells, NK cells 
Activates macrophages; increases 
expression of MHC class I and class II 
molecules; increases antigen presentation; 
weak antiviral and anti-proliferative 
activities 
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3.4 RESULTS 
Mean age (range: 40 – 46 years) was different (p<0.01) across the four HIV/HCV 
groups and study participants were two-thirds non-white and three quarters male. 
Evidence of liver fibrosis, diabetes, and CVD was highest among those with HCV 
whereas at-risk alcohol consumption and immunodeficiency were highest among those 
with detectable HIV RNA (Table 11). Median biomarker levels were generally highest 
among those with both HIV and HCV detectable (Table 12) – likewise for those with 
highest levels of inflammatory burden (Table 13). Significant (p<0.05) correlations were 
observed between HIV RNA and IL-10, TNF-α, cystatin C (Table 14). 
Participants in the undetectable group were least likely to have concurrently 
elevated biomarkers (inflammatory burden score = 2 or 3), while those in the HIV/HCV 
detectable group were most likely (Figure 5). For individual biomarkers, the prevalence 
of elevated IL-10, TNF-α, cystatin C, and IL-6 was significantly different across the four 
HIV/HCV groups (p<0.05, Figure 5). The highest proportions of elevated IL-10, TNF-α, 
and cystatin C occurred in the HIV/HCV detectable group (Figure 5). The HCV mono- 
detectable group had the highest proportion of elevated IL-6 (Figure 5). The prevalence 
of elevated CRP, SAA, IFN-γ and MCP-1 was similar across the four groups (p>0.05, 
Figure 5). 
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Table 11: Characteristics of 361 HIV-LIVE participants with HIV infection and alcohol problems 
stratified by detectable HIV and HCV viremia. 
Subject 
characteristics 
HIV/HCV RNA 
both undetectable 
(N=59) 
HIV RNA 
only 
detectable 
(N=122) 
HCV RNA 
only 
detectable 
(N=53) 
HIV/HCV 
RNA both 
detectable 
(N=127) 
p- 
value 
Age in years, mean 
(SD) 43 (7) 40 (8) 46 (7) 43 (7) <0.01 
Female 16 (27.1) 26 (21.3) 11 (20.8) 35 (27.6) 0.59 
Race, Non-White 42 (71.2) 84 (68.9) 34 (64.2) 84 (66.1) 0.84 
FIB-4 ≥ 1.45 7 (16.3) 28 (28.2) 22 (59.4) 52 (54.7) <0.01 
FIB-4, Median (Min, 
Max) 0.9 (0.5, 3.1) 1.1 (0.2, 7.5) 1.6 (0.7, 14.9) 1.6 (0.4, 17.1) 0.30 
Mean (Standard 
Deviation) 1.1 (0.5) 1.3 (1.0) 2.8 (2.9) 2.3 (2.2) 
N 43 99 37 95 
Current at-risk 
alcohol consumption 15 (25.4) 46 (38.0) 9 (17.0) 43 (33.9) 0.03 
Current CD4+ T- 
lymphocyte count 
<200 cells/mm3 
4 (6.8) 27 (22.9) 6 (11.8) 34 (26.8) <0.01 
Current 
antiretroviral 
medication 
52 (88.1) 56 (45.9) 50 (94.3) 65 (51.2) <0.01 
BMI ≥30kg/ m2 13 (22.8) 23 (19.8) 8 (15.1) 25 (21.2) 0.76 
Prevalent 
cardiovascular 
disease 
3 (5.1) 2 (1.6) 6 (11.3) 15 (11.9) <0.01 
Ever had diabetes 2 (3.4) 6 (4.9) 9 (17.0) 9 (7.1) 0.02 
Ever had 
hypertension 16 (27.1) 28 (23.0) 14 (26.4) 33 (26.0) 0.91 
Ever had high 
cholesterol 29 (49.2) 32 (26.2) 11 (20.8) 25 (19.7) <0.01 
Ever had kidney 
disease 2 (3.4) 5 (4.1) 5 (9.4) 9 (7.1) 0.40 
Ever anemic 17 (28.8) 28 (23.0) 12 (22.6) 31 (24.4) 0.84 
Current smoker 39 (66.1) 93 (76.2) 40 (75.5) 102 (80.3) 0.22 
Ever cocaine use 23 (39.0) 53 (43.4) 18 (34.0) 65 (51.2) 0.14 
Ever injection drug 
use 10 (17.0) 26 (21.5) 46 (86.8) 115 (90.6) <0.01 
Ever treated hepatitis 
C 0 (0) 3 (2.5) 8 (15.1) 6 (4.7) <0.01 
All values are n (% of HIV/HCV group) unless otherwise specified 
HIV-human immunodeficiency virus; HCV-hepatitis C virus; FIB-4-liver fibrosis index- 
4; BMI-body mass index 
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Table 12: Distribution of biomarkers by HIV/HCV viremia status 
HIV & HCV 
Detectable 
HIV Only 
Detectable 
HCV Only 
Detectable 
HIV & HCV 
Undetectable 
IL-10 pg/ml 6.50 (6.76) 5.00 (4.88) 6.30 (4.85) 2.85 (2.27) 
TNFa pg/ml 7.96 (6.35) 7.64 (4.52) 6.59 (3.6) 4.88 (3.23) 
Cystatin C mg/l 0.87 (0.24) 0.76 (0.21) 0.77 (0.18) 0.67 (0.19) 
IL-6 pg/ml 3.24 (3.48) 2.35 (2.12) 3.86 (4.89) 1.89 (2.36) 
CRP mg/l 1.08 (2.63) 1.73 (2.86) 1.89 (3.82) 2.06 (2.47) 
SAA mg/l 3.00 (5.1) 3.35 (4.65) 3.00 (4.2) 3.20 (4.8) 
IFNg pg/ml 0.12 (0) 0.12 (0) 0.12 (0) 0.12 (0) 
MCP-1 pg/ml 563.13 (393.62) 623.08 (474.23) 520.78 (425.81) 544.39 (347.77) 
Table 13: Distribution of biomarkers by inflammatory burden score 
No Elevated 
Biomarkers 
1 Elevated 
Biomarker 
2 Elevated 
Biomarkers 
3+ Elevated 
Biomarkers 
IL-10 pg/ml 3.13 (2.67) 4.49 (4.32) 5.46 (4.61) 8.39 (8.68) 
TNFa pg/ml 4.89 (2.21) 6.23 (4.01) 7.86 (5.37) 9.84 (6.33) 
Cystatin C mg/l 0.65 (0.17) 0.77 (0.18) 0.82 (0.21) 0.93 (0.4) 
IL-6 pg/ml 1.45 (1.54) 2.05 (1.96) 3.25 (2.8) 5.53 (6.91) 
CRP mg/l 0.82 (1.73) 1.13 (1.55) 1.67 (3.33) 3.49 (5.94) 
SAA mg/l 2.15 (2.2) 2.60 (3.4) 3.65 (4.4) 6.35 (8.9) 
IFNg pg/ml 0.12 (0.0) 0.12 (0.0) 0.12 (0.0) 0.12 (0.2) 
MCP-1 pg/ml 460.69 (270.33) 543.83 (392.52) 644.18 (544.09) 746.73 (483.7) 
69 
Table 14: Correlations between biomarkers and HIV/HCV viremia 
Spearman Correlation Coefficients 
Prob > |r| under H0: Rho=0 
Number of Observations 
HIV-1 RNA Hepatitis C RNA 
IL-10 pg/mL 
0.31 0.07 
<0.01 0.36 
313 192 
TNFa pg/mL 
0.31 0.04 
<0.01 0.59 
313 192 
Cystatin C_mg/L 
0.28 0.09 
<0.01 0.23 
313 192 
IL-6_pg/ml 
0.09 0.04 
0.11 0.62 
281 170 
CRP mg/L 
0.02 -0.11 
0.68 
313 
0.15 
192 
SAA_mg/L 
0.05 0.11 
0.42 0.16 
298 183 
IFNg pg/mL 
-0.03 -0.04 
0.55 0.57 
313 192 
MCP-1 pg/mL 
0.09 0.16 
0.11 0.03 
313 192 
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Figure 5: Inflammatory burden scores (number of elevated biomarkers) and individually elevated 
biomarkers by HIV/HCV group. 
Elevated individual biomarkers were defined as a serum biomarker level >75th 
percentile. Inflammatory burden score was defined as the presence of zero, one, two, or 
three or more elevated biomarkers. For individual biomarkers, the prevalence of elevated 
IL-10, TNF-α, IL-6 and cystatin C was significantly different across the four HIV/HCV 
groups (p<0.05). 
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Compared to participants with undetectable HIV and HCV RNA, those in the 
HIV mono-detectable group (proportional odds ratio (POR)=1.89 (95% confidence 
interval (CI) 1.03-3.46), HCV mono-detectable group (POR=2.70, 95% CI=1.29-5.68), 
and HIV/HCV detectable group (POR=3.48, 95% CI=1.87-6.46) had a significantly higher 
inflammatory burden (Table 15). This association persisted among participants in the 
HCV mono detectable and HIV/HCV detectable groups after adjusting for potential 
confounders (Table 15). FIB4 score ≥1.45 was also significantly associated with an 
increased burden of inflammatory biomarkers (p<0.01, Table 15). 
Compared to the undetectable group, the HIV/HCV RNA detectable group had 
higher prevalence of elevated IL-10, TNF-α, IL-6, and cystatin C. After adjustment for 
potential confounders, this association remained significant for IL-10 (OR=7.79, 95% 
CI=1.90-31.97) and TNF-α (OR=7.70, 95% CI=1.42-41.83, Table 16). Elevations in 
CRP, SAA, IFN-γ, and MCP-1 were not significantly different in any HIV/HCV group 
compared to the undetectable group in either the unadjusted or adjusted models (Table 
16). 
FIB-4 ≥1.45 was significantly associated with elevated cystatin C (OR=3.43, 
95% CI= 1.45-8.10), IL-6 (OR=3.22, 95% CI= 1.44-7.20) 114  and MCP-1 (OR=2.39, 
95% CI=1.10- 5.20). Age above the median (42 years) was associated with lower odds 
of elevated IL-10, self-reported high cholesterol and diabetes with higher odds of 
elevated TNF-α, and current ART use with lower odds of elevated TNF-α. Self-reported 
CVD and smoking were associated with higher odds of elevated cystatin C, and self-
reported renal disease with higher odds of elevated SAA and cystatin C. BMI ≥30 kg/m2 
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was associated with higher odds of elevated CRP, and female gender with lower odds of 
elevated MCP-1 (p<0.05 for all; Table A2). 
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Table 15: Association of HIV/HCV group with concurrently elevated (>75th percentile) 
inflammatory biomarkers. 
Model A (N=218) Unadjusted  Adjusteda  
POR (95% CI) p-value POR (95% CI) p-value 
Undetectable 1 -- 1 -- 
HIV mono-detectable 1.89 (1.03, 3.46)  0.04 1.52 (0.68, 3.41) 0.31 
HCV mono-detectable 2.70 (1.29, 5.68)  <0.01 2.95 (1.08, 8.01) 0.03 
HIV/HCV detectable 3.48 (1.87, 6.46)  <0.01 2.49 (1.05, 5.89) 0.04 
FIB-4 ≥ 1.45 -- -- 2.56 (1.39, 4.35) <0.01 
High cholesterol -- -- 1.74 (0.97, 3.14) 0.06 
Age greater than median (42 yrs) -- -- 0.61 (0.36, 1.04) 0.07 
BMI ≥ 30 kg/m2 -- -- 1.81 (0.93, 3.54) 0.08 
Ever smoker -- -- 1.53 (0.85, 2.78) 0.16 
CD4 > 200 cells/mm3 -- -- 0.63 (0.31, 1.26) 0.19 
Renal disease -- -- 2.15 (0.67, 6.86) 0.20 
Diabetes -- -- 1.90 (0.58, 6.21) 0.29 
Current antiretroviral therapy use -- -- 0.74 (0.42, 1.31) 0.30 
Prevalent cardiovascular disease -- -- 1.82 (0.56, 5.97) 0.32 
Hypertension -- -- 0.78 (0.42, 1.45) 0.44 
At-risk alcohol consumption -- -- 0.94 (0.55, 1.62) 0.83 
Female -- -- 1.03 (0.55, 1.94) 0.93 
aModel adjusted for age, gender, FIB-4 score, at-risk drinking, CD4 count, ART use, and 
self-reported comorbidity. 
The ordinal logistic regression model estimates the proportional odds of having more 
than N concurrently elevated biomarkers versus N or fewer where N=0, 1, 2, or 3 or 
more. 
POR-proportional odds ratio; HIV-human immunodeficiency virus; HCV-hepatitis C 
virus; FIB-4- liver fibrosis index-4; BMI-body mass index; CD4-CD4+ T-lymphocyte 
count 
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Table 16: Association of HIV/HCV group with individually elevated (>75th percentile) biomarkers. 
Biomarker elevated HIV/HCV group Unadjusted OR (95% CI) 
Adjusted ORa (95% 
CI) 
Model B (N=218) Undetectable 1 1 
Interleukin-10 
HIV mono-detectable 4.74* (1.36, 16.48) 2.95 (0.74, 11.85) 
HCV mono- 
detectable 5.39* (1.39, 20.84) 5.51* (1.17, 25.84) 
HIV/HCV detectable 9.22* (2.69, 31.55) 7.79* (1.90, 31.97) 
Model C (N=218) Undetectable 1 1 
Tumor necrosis factor-α 
HIV mono-detectable 4.50* (1.29, 15.70) 4.44 (0.86, 22.82) 
HCV mono- 
detectable 4.15* (1.04, 16.47) 4.45 (0.68, 29.02) 
HIV/HCV detectable 8.50* (2.48, 29.16) 7.70* (1.42, 41.83) 
Model D (N=196) Undetectable 1 1 
Interleukin-6 
HIV mono-detectable 1.33 (0.49, 3.66) 0.57 (0.15, 2.16) 
HCV mono- 
detectable 5.17* (1.79, 14.94) 2.99 (0.75, 11.98) 
HIV/HCV detectable 3.33* (1.28, 8.70) 1.47 (0.40, 5.35) 
Model E (N=218) Undetectable 1 1 
Cystatin-C 
HIV mono-detectable 1.50 (0.56, 4.01) 0.49 (0.12, 2.02) 
HCV mono- 
detectable 2.22 (0.73, 6.73) 0.40 (0.07, 2.34) 
HIV/HCV detectable 5.04* (1.98, 12.85) 1.60 (0.39, 6.57) 
Model F (N=218) Undetectable 1 1 
C-reactive protein 
HIV mono-detectable 1.16 (0.54, 2.51) 0.99 (0.35, 2.84) 
HCV mono- 
detectable 1.09 (0.42, 2.80) 1.41 (0.41, 4.90) 
HIV/HCV detectable 0.86 (0.39, 1.90) 0.69 (0.22, 2.14) 
Model G (N=210) Undetectable 1 1 
Serum amyloid A 
HIV mono-detectable 0.81 (0.36, 1.80) 0.58 (0.19, 1.79) 
HCV mono- 
detectable 0.69 (0.25, 1.89) 0.38 (0.09, 1.66) 
HIV/HCV detectable 1.01 (0.46, 2.22) 0.72 (0.22, 2.31) 
Model H (N=218) Undetectable 1 1 
Interferon-γ 
HIV mono-detectable 1.40 (0.52, 3.78) 1.65 (0.46, 5.87) 
HCV mono- 
detectable 1.68 (0.53, 5.28) 2.63 (0.59, 11.76) 
HIV/HCV detectable 0.92 (0.32, 2.60) 1.03 (0.25, 4.30) 
Model I (N=218) Undetectable 1 1 
Monocyte chemoattractant 
protein-1 
HIV mono-detectable 1.67 (0.72, 3.84) 2.96 (0.80, 10.95) 
HCV mono- 
detectable 1.38 (0.50, 3.79) 3.71 (0.83, 16.53) 
HIV/HCV detectable 1.37 (0.59, 3.21) 3.48 (0.88, 13.69) 
aModels adjusted for age, gender, FIB-4 score, at-risk drinking, CD4 count, ART use, and self- 
reported comorbidity. See Table A2 for odds ratios for covariates. 
75 
 
 
 
 
3.5 DISCUSSION 
 
 
 
 
This study suggests that HIV and HCV viremia contribute to elevations in 
inflammatory burden score, IL-10 and TNF-α, independently of and in addition to the 
contribution from comorbid conditions. Our results also suggest that a composite measure, 
comprising multiple inflammatory biomarkers, may suggest an inflammatory state is 
present even when individual biomarkers do not. The fact that there was no significant 
association between any HIV/HCV group and CRP or SAA, two biomarkers synthesized in 
the liver, suggests a need for caution when using these biomarkers to assess inflammation 
in this population with high potential for liver morbidity. 
This study differs from prior work 115-123 in that it attempts to classify people as 
having more or less inflammation using a concomitantly elevated panel of inflammatory 
biomarkers rather than emphasizing one individual biomarker of inflammation. Additionally, 
our results may be more definitive these prior studies because of our detailed data on 
alcohol consumption and the inclusion of a validated measure of liver fibrosis. 
Findings from our study are consistent with those from prior studies investigating 
the association between HIV/HCV status and TNF-α 115-118, CRP 119,120, IL-10 118,121, IFN-γ 
118,122,124, IL-6 116 and cystatin C 123. However, some differences between our work and these 
prior studies may reflect different biomarker outcome categorization (quartiles versus 
detection, secretion, ormeans), HIV/HCV categorization (viremia versus antibody detection, 
in vitro stimulation with viral proteins) sources of biomarkers (serum versus intrahepatic), 
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viral proteins) sources of biomarkers (serum versus intrahepatic), referent groups (participants 
with undetectable HIV and HCV viremia versus HIV or HCV mono-infected participants) and 
adjustment covariates. The strong associations we reported between detectable viremia and the 
anti-inflammatory cytokine, IL-10, are consistent with prior research linking persistent viral 
infection with increased IL-10 production 125. The lack of data comparing MCP-1, or SAA levels 
by HIV/HCV status suggests that our findings for these particular cytokines may be novel. 
The present study and other work has shown that factors including viral replication, 
immunocompetence, comorbidity 61,67,68,102, ART 61,67 and ART hepatotoxicity 126, contribute to 
alterations in some inflammatory biomarkers but not others. If the current study had only 
investigated CRP, a clinically used inflammatory biomarker 127, we may have concluded that 
detectable HIV and HCV viremia were not associated with increased inflammation. To more 
completely describe inflammation, we propose that research into the inflammatory basis of 
morbidity and mortality should also use composite measures of inflammatory biomarkers. These 
biomarkers often reflect overlapping biological processes involved in the immune response. 
Concurrently using multiple biomarkers potentially reduces the variability (intra and inter- 
person) inherent in measuring and analyzing individual biomarkers. Using single biomarkers to 
quantify systemic inflammation may be most appropriate in populations with minimal 
inflammatory comorbid disease. However, a composite measure of inflammation may be more 
appropriate in HIV-infected populations, where multi-morbidity contributes strongly to chronic 
systemic inflammation. Future research should compare the contributions of composite versus 
individual inflammatory biomarker measures to CVD morbidity and mortality prediction. 
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Strengths of our study include a large, diverse panel of inflammatory biomarkers. Our 
study sample had well characterized measures of current or past alcohol problems, an important 
comorbid condition in HIV populations. We had a large proportion of non-white individuals 
(>50%) enabling generalizability to important minority populations. Limitations that warrant 
discussion include the lack of HIV uninfected controls, the cross sectional nature of this study, 
self-reported measures of health conditions, and lack of direct cell surface immune activation 
data for comparison to serum cytokine data. Sample size limitations may explain the strong but 
non-significant associations of covariates like high cholesterol, renal disease and smoking with 
inflammatory burden. This limitation may also explain the stronger association of the HCV 
mono-detectable group with inflammatory burden versus the HIV/HCV detectable group. As 
with all observational studies, we cannot exclude the potential for residual confounding. 
3.6 CONCLUSION 
In a cohort of HIV infected people with current or past alcohol problems, detectable HIV 
and HCV RNA compared to undetectable viremia was associated with greater systemic 
inflammation as measured by an inflammatory burden score and elevations in certain 
inflammatory biomarkers. This association was independent of at-risk drinking, liver fibrosis and 
other comorbidities. 
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4.1 ABSTRACT 
Introduction: HIV infection is an independent predictor of acute myocardial infarction (AMI) 
with a magnitude of association similar to that of diabetes mellitus. In the general population, 
current guidelines recommend more aggressive treatment of prehypertension among those with 
diabetes or renal disease to prevent future cardiovascular disease (CVD). Similar rationale may 
apply to HIV infection. The objective of this study was to examine whether the association 
between elevated blood pressure and risk for AMI differed by HIV status. 
Methods: We analyzed data on 81,030 people from the observational Veterans Aging Cohort 
Study Virtual Cohort (VC), who were free of CVD at baseline. HIV infected (HIV+) and 
uninfected Veterans were matched 1:2 on age, gender, race/ethnicity, and clinical site. We 
collected data on systolic and diastolic blood pressure, antihypertensive medications, diabetes, 
dyslipidemia, smoking, hepatitis C, body mass index, renal disease, and substance abuse at 
baseline and on the incidence of clinically confirmed AMI from 10/2003-9/2008. Blood pressure 
was the average of the three outpatient routine clinical blood pressure measurements performed 
closest to the baseline date (first clinical visit after 4/2003). Blood pressure categories used in the 
analyses were based on JNC- VI and VII criteria. Analyses were performed using Cox 
proportional hazards regression. 
Results: Over a median of 5.9 years, 860 incident AMIs occurred. AMI rates were higher among 
HIV+ compared to uninfected Veterans within almost all blood pressure categories. Low/high 
prehypertensive and untreated/treated hypertensive individuals had increased AMI risk compared 
to uninfected untreated normotensive individuals [Hazard Ratio [HR]: 1.60; 95% confidence 
interval (CI): 1.07-2.39; HR:1.80 (1.21-2.68); HR: 2.57 (1.76-3.76); HR: 2.75 (1.89-4.00) 
respectively] 
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Conclusions: Given the increased risk of AMI, diabetes, and renal disease associated with HIV 
infection and if our results are confirmed in other studies, future research should explore whether 
lower blood pressure targets among HIV+ people translates into lower AMI risk in a randomized 
controlled trial. 
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4.2 INTRODUCTION 
For certain high cardiovascular disease (CVD) risk populations like people with diabetes 
or chronic kidney disease, more aggressive blood pressure control is recommended to prevent 
future CVD events
128
. Compared to uninfected people, HIV infected (HIV+) people have an
increased risk of acute myocardial infarction (AMI)
129-131
 as well as diabetes
132
 and chronic renal
disease
133
. However there are no specific guidelines for blood pressure management among
HIV+ people. Whether HIV+ people have increased AMI risk even at prehypertension levels 
compared to uninfected people is not known. The objective of this study was to examine the 
relationship among HIV status, blood pressure, and the risk of AMI and to determine if HIV 
infected people with prehypertension had an increased risk of AMI compared with uninfected 
people. 
4.3 METHODS 
4.3.1 Subject selection 
The Veterans Aging Cohort Study Virtual Cohort (VACS VC)
134
 is a prospective
longitudinal cohort of HIV+ Veterans each matched on age, race/ethnicity, and clinical site to 
two uninfected Veterans in care. Subjects have been continuously enrolled in each year since 
1998 using a validated existing algorithm from United States Department of Veterans Affairs 
84 
(VA) national electronic medical record system 
134
. The institutional review boards at the 
University of Pittsburgh, Yale University, and the West Haven VAMC approved this study. 
All VACS VC participants who were alive and enrolled in VACS VC on or after 2003 
were eligible for this study. Baseline was a participant’s first clinical encounter on or after 
4/1/2003.  All participants were followed from their baseline date to an AMI event, death, or the 
date of last follow-up (1/1/2010). 
These AMI data were merged with AMI data from Medicare and the Ischemic Heart 
Disease Quality Enhancement Research Initiative (IHD-QUERI), an initiative designed to 
improve the quality of care and health outcomes of Veterans with IHD 
71,135
. We excluded any
participant who had prevalent CVD based on ICD-9 codes for AMI, unstable angina, 
cardiovascular revascularization, stroke or transient ischemic attack, peripheral vascular disease 
or heart failure up to six months after their baseline line date (N=17,229) 
72,136
. After this 
exclusion, 81,030 Veterans (33% HIV+) with available blood pressure data were included for 
this study. 
4.3.2 Independent variable 
Systolic blood pressure (SBP), diastolic blood pressure (DBP) and antihypertensive 
medication prescription were used to create the independent variables. SBP and DBP were 
averaged across the three routine outpatient clinical blood pressure measurements performed 
closest to the baseline date. Data on antihypertensive medication were obtained from the 
pharmacy management benefits package. Blood pressure status was based on the Sixth and 
Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure (JNC VI and VII) 
128,137
: Normal (SBP 90-120 and DBP 60-
85 
80 mmHg and no antihypertensive medication prescription), low-hypertension (SBP 120-129 or 
DBP 80-84 mmHg and no antihypertensives), high-prehypertension (SBP 130-139 or DBP 85-89 
mmHg and no antihypertensives), hypertension (SBP≥ 140 or DBP ≥100 mmHg and no 
antihypertensives), treated hypertension. Participants were classified as being in the higher 
category if SBP and DBP fell in different categories. 
While JNC VII represents the most current blood pressure management guidelines, we 
applied the prehypertension criteria from JNC VI for a more detailed description of people with 
elevated blood pressure but without frank hypertension. JNC VII incorporated the normal and 
high-normal blood pressure categories from JNC VI into the prehypertension category. We 
renamed these as low and high prehypertension to avoid confusion with JNC VII terminology. 
HIV infection was present if a participant had ≥1 inpatient and/or ≥2 outpatient ICD-9 codes for 
HIV infection and was included in the VA Immunology Case Registry.
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4.3.3 Dependent variable 
The definition of AMI incidence has previously been described 
129
. Briefly AMI 
incidence was determined using VA, Medicare and death certificate data. AMI events in the VA 
were collected by trained abstractors from the VA External Peer Review program 
71,138
. Clinical
confirmation required documentation of AMI in the discharge summary followed by a review of 
the physician notes and medical chart. Medical information abstracted included evidence of 
elevated serum markers of myocardial damage and EKG findings. Non-VA AMI events were 
captured using ICD-9 code, 410, which had strong agreement with adjudicated AMI outcomes in 
the Cardiovascular Health Study (CHS)
72
. Based on CHS criteria we defined definite or possible
fatal AMI as a death within four weeks of a clinically confirmed AMI or a death certificate 
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documenting AMI as the underlying cause (ICD-10 code I21.0-I21.9) respectively.  Deaths were 
identified using the VA vital status file, the Social Security Administration death master file, the 
Beneficiary Identification and Records Locator Subsystem, and the Veterans Health 
Administration medical Statistical Analysis Systems inpatient datasets. Cause of death was 
obtained from the National Death Index on 94.2% and 95.5% of HIV+ and uninfected decedents, 
respectively. 
4.3.4 Covariates 
Sociodemographic data included age, sex, and race/ethnicity. Framingham CVD risk 
factors including diabetes
139
, hyperlipidemia (i.e., low density (LDL), high density (HDL)
lipoprotein cholesterol and triglycerides) were measured using outpatient and clinical laboratory 
data collected closest to the baseline date. Smoking was measured from the VA Health Factors 
data repository
75
 using a standardized form within the VA. For other CVD risk factors: HMG-
CoA reductase inhibitor use was based on pharmacy data, body mass index (BMI) was measured 
from Health Factors data, renal disease and anemia were measured using outpatient and clinical 
laboratory data collected closest to the baseline date. Hepatitis C (HCV) infection was defined as 
a positive HCV antibody test or ≥1 inpatient and/or ≥2 outpatient ICD-9 codes for this 
diagnosis
78
. History of cocaine and alcohol abuse or dependence was defined using ICD-9
codes
140
.
Specifically, diabetes was diagnosed using glucose measurements, use of insulin or oral 
hypoglycemic agents, and/or ≥1 inpatient and/or 2 outpatient ICD-9 codes74. Hyperlipidemia
variables were categorized based on National Cholesterol Education Program Adult Treatment 
Panel III criteria 
76
. Cholesterol measurements were obtained from the VA Decision Support
87 
System (DSS). Renal disease was defined as an estimated glomerular filtration rate (eGFR) of 
less than 60 mL/min/1.73m
2
 per National Kidney Foundation Kidney Disease Outcomes Quality
Initiative thresholds for chronic kidney disease
79
. Smoking was categorized into current, past,
and never smoking. 
For HIV specific covariates, we collected data on HIV-1 RNA, CD4+ T-lymphocyte 
counts (CD4+ cell counts), and current use of highly active antiretroviral therapy (HAART). We 
used CD4+ cell counts and HIV-1 RNA measurements obtained as part of clinical care from 
within 180 days of our baseline date. We included all ART medications that were on VA 
formulary during the study period. We have previously shown in a nested sample that 98% of 
HIV+ Veterans on ART obtain their medications from the VA
134
.
4.3.5 Statistical Analyses 
Variables were compared by HIV and blood pressure category using Kruskall-Wallis, 
Wilcoxon rank sum tests, or chi-square tests as appropriate. We calculated unadjusted and age 
and race/ethnicity adjusted AMI rates per 10,000 person years (py) for each blood pressure 
category overall and by HIV status using Poisson regression models. Using Cox proportional 
hazard models, we estimated hazard ratios (HR) and 95% confidence intervals (CI) to assess 
whether HIV combined with blood pressure category was an independent risk factor for incident 
AMI after adjusting for age, sex and race/ethnicity. We additionally adjusted these analyses for 
traditional CVD risk factors (diabetes, lipids, smoking), comorbid diseases (HMG CoA reductase 
inhibitor use, HCV infection, renal disease, anemia, obesity) and substance use or abuse 
(cocaine, alcohol). We accounted for antiretroviral therapy, HIV viremia and immune status in 
models restricted to HIV infected participants. 
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In secondary analyses, we investigated the impact of widening pulse pressure (systolic 
minus diastolic blood pressure) and HIV on AMI risk. 
Missing covariate data were included in the analyses using multiple imputation 
techniques that generated five data sets with complete covariate values to increase the robustness 
of the estimated hazard ratios. Analyses were performed using (Stata v11.0 StataCorp).
4.4 RESULTS 
Of 81,030 Veterans with available blood pressure data, 16% were categorized as normal, 
44% as prehypertensive (half of whom had high-prehypertension) and 39% as hypertensive. 
Mean age ranged from 47 to 53 years. Compared to Veterans with normal blood pressure, those 
with prehypertension or hypertension had greater prevalence of diabetes, and triglycerides, HMG 
CoA inhibitor use, BMI ≥30 kg/m2 but less prevalent cocaine use. Hypertensive Veterans were
older and had more prevalent renal dysfunction than normotensive Veterans (Table 17).  HIV+ 
Veterans had a higher prevalence of low HDL, high triglycerides, low hemoglobin and hepatitis 
C, but less diabetes and BMI ≥30 kg/m2 than uninfected Veterans (Table 17). HAART use was
similar across blood pressure categories. Median CD4+ T-cell counts were higher and HIV-1 
RNA was lower among those with elevated blood pressure compared to those with normal blood 
pressure (Table 17). 
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Table 17: Baseline characteristics of study population 
Normotension† 
(90-119)/(60-79) mmHg 
Prehypertension 
(120-139)/(80-89) mmHg 
Hypertension 
≥140/90 no BP meds 
Hypertension 
(on BP meds) 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
N 7634 5722 23477 12065 11021 4613 11425 4257 
Demographics 
Age in years, mean 
(SD) 
47.0 (8.5) 47.0 (8.7) 47.0 (9.0) 47.0 (9.3) 49.0 (9.0) 49.0 (9.6) 53.0 (8.9) 53.0 (8.9) 
Female 5 4 3 3 2 2 2 2 
Race 
African American 47 48 44 45 48 47 57 58 
White 38 36 41 41 38 39 32 31 
Hispanic 10 10 8 7 7 6 7 6 
Other 6 7 7 7 7 8 4 5 
Framingham risk 
factors 
Systolic blood 
pressure in mmHg, 
mean (SD) 
114.0 (5.3) 113.3 (5.8) 129.3 (5.9) 128.5 (6.0) 
145.7 
(10.0) 
145.0 (9.4) 
140.0 
(15.6) 
140.0 (16.9) 
Diastolic blood 
pressure in mmHg, 
mean (SD) 
70.3 (4.9) 70.0 (4.9) 78.3 (6.2) 78.0 (6.2) 87.7 (8.2) 87.7 (8.1) 83.3 (10.0) 83.3 (10.8) 
Diabetes 11 8 16 11 20 16 39 30 
LDL cholesterol 
Optimal (<100 
mg/dL) 
32 49 30 44 29 44 37 50 
Near optimal (100-
129 mg/dL) 
35 30 33 30 33 31 33 28 
Borderline high (130-
159mg/dL) 
22 14 24 17 24 16 20 14 
High/Very high (≥160 
mg/dL) 
11 7 13 9 14 9 10 7 
HDL cholesterol 
High (≥60 mg/dL) 18 11 14 11 16 12 13 11 
Medium (40-59 49 37 48 38 47 38 45 36 
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Normotension† 
(90-119)/(60-79) mmHg 
Prehypertension 
(120-139)/(80-89) mmHg 
Hypertension 
≥140/90 no BP meds 
Hypertension 
(on BP meds) 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
mg/dL) 
Low (<40 mg/dL) 34 53 38 51 37 50 42 52 
Triglycerides ≥150 
mg/dL  
29 41 38 47 41 53 42 50 
HMG-CoA reductase 
inhibitor use 
6 4 8 6 8 7 18 11 
Smoking 
Current 59 66 54 59 56 58 48 56 
Past 12 11 15 13 16 13 20 16 
Never 28 23 30 27 28 29 33 28 
Other risk factors 
BMI ≥30 kg/m2 21 8 37 15 45 21 53 24 
Renal disease 
EGFR≥60 
mL/min/1.73 m2 
98 96 97 96 96 94 89 82 
EGFR 30-59 
mL/min/1.73 m2 
2 4 3 4 4 5 9 12 
EGFR <30 
mL/min/1.73 m2 
0 0 0 1 0 1 2 6 
Anemia 
Hemoglobin ≥14 
mg/dL 
71 49 76 60 75 61 64 45 
Hemoglobin 12-13.9 
mg/dL 
24 35 21 30 21 30 29 35 
Hemoglobin 10-11.9 
mg/dL 
4 12 2 7 3 7 6 14 
Hemoglobin <10 
mg/dL 
1 4 1 2 1 2 2 6 
HIV-related risk 
factors 
HCV infection 17 36 15 32 16 34 17 44 
Cocaine 10 13 7 11 6 9 6 13 
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Normotension† 
(90-119)/(60-79) mmHg 
Prehypertension 
(120-139)/(80-89) mmHg 
Hypertension 
≥140/90 no BP meds 
Hypertension 
(on BP meds) 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
HIV 
uninfected 
HIV 
infected 
abuse/dependence 
Alcohol 
abuse/dependence 
15 15 13 13 13 12 14 18 
On HAART at 
baseline 
43 45 44 45 
HIV specific 
biomarkers 
CD4+ T lymphocyte 
count (cells/mm3) 
≥ 500 27 34 34 32 
200-499 39 41 40 41 
<200 34 26 26 27 
Median, mean ± SD 
314 
 (359±295) 
369 
(415±303) 
374 
(413±298) 
365 
(414±304) 
HIV RNA 
(copies/mL) 
≥ 500 60 55 54 52 
Median, (mean ± SD 
*10^4)
0.3 
(7.9±22.0) 
0.1 
(5.6±18.4) 
0.09 
(46.2±12.1) 
0.07 
(49.4±13.3) 
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Over a median of 5.9 years, 860 incident AMIs occurred. AMI rates and risk increased 
with increasing blood pressure (Figure 6, Table 18) among HIV infected and uninfected Veterans 
(Table 19). These associations persisted among HIV infected Veterans even after adjustment for 
HIV-1 RNA, CD4+ cell count and/or HAART use (Table A3). 
There was evidence of additive interaction between blood pressure and HIV status on 
AMI since AMI rates were higher than would have been expected from HIV or elevated blood 
pressure alone (Figure 7). However, no significant multiplicative interactions (p>0.05) were 
observed even when blood pressure was considered as a continuous systolic or diastolic measure. 
Compared to uninfected Veterans with normal blood pressure, HIV+ Veterans with low 
or high prehypertension or hypertension had significantly increased AMI risk [Hazard Ratio 
[HR]: 1.60; 95% confidence interval (CI): 1.07-2.39; HR:1.80 (1.21-2.68); HR: 2.57 (1.76-3.76); 
HR: 2.75 (1.89-4.00) respectively] after adjustment for confounders (Table 20). Results were 
similar when systolic and diastolic blood pressure were analyzed separately (Table A4). 
A 10 mmHg increase in pulse pressure was associated with a small but significantly 
increased risk of AMI: 1.12 (1.06-1.19); p<0.001) after adjusting for confounders. HIV infection 
did not modify the association between pulse pressure and AMI risk [HR (95% CI) for 
interaction: 0.92 (0.83-1.03), data otherwise not shown]. 
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Figure 6: Unadjusted rate of incident AMI by systolic and diastolic blood pressure increments stratified by 
HIV status or antihypertensive therapy 
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Table 18: Rate & risk of incident AMI (95% CI) by blood pressure status 
Blood Pressure  
Category (mmHg) 
Definition 
N 
# of 
AMIs 
Age/race adjusted AMI 
rate/10,000py 
Hazard Ratio (95% CI) 
Adjusted for age, sex, 
race/ethnicity 
Adjusted for all 
covariates* JNC VII JNC VI 
<90/60† Hypotension Hypotension 846 7 18.6 (8.8-39.7) 1.34 (0.62-2.90) 1.31 (0.61-2.84) 
90-119/60-79† Normal Optimal 13356 82 12.8 (9.9-16.4) 1 1 
120-129/80-84 
Pre 
hypertension 
Low 
prehypertension 
17813 123 13.8 (11.1-17.3) 1.09 (0.83-1.44) 1.11 (0.84-1.46) 
130-139/85-89 
High-
prehypertension 
17699 156 17.5 (14.3-21.5) 1.33 (1.01-1.73) 1.35 (1.03-1.77) 
≥140/90 
Hypertension 
(Stages 1 -2) 
Hypertension 
(Stages 1-3) 
15634 190 24.5 (20.3-29.8) 1.72 (1.32-2.23) 1.69 (1.29-2.20) 
Use of antihypertensive 
medication 
Hypertension 
(Stages 1 -2) 
Hypertension 
(Stages 1-3) 
15682 302 39.1 (33.1-46.1) 2.34 (1.82-3.00) 2.03 (1.57-2.64) 
All covariates includes age, sex, and race/ethnicity, LDL, HDL, triglycerides, diabetes, HMG CoA reductase inhibitor use, HCV infection, renal disease, anemia, 
BMI, cocaine, and alcohol use 
† We included people with SBP<90 mmHg or DBP<60 mmHg as a separate category because in our cohort, such low blood pressure indicates hypotension 
instead of normotension. 
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Table 19: Rate & risk of incident AMI (95% CI) by blood pressure status among HIV infected and uninfected Veterans (separate reference groups) 
Blood Pressure  
Category (mmHg) 
Definition 
Hazard Ratio (95% CI) 
Adjusted for all covariates* 
HIV- HIV+ 
<90/60† Hypotension 1.67 (0.6-4.67) 
1.05 (0.32-3.39) 
90-119/60-79† Normal 1 1 
120-129/80-84 Low prehypertension 0.99 (0.67-1.47) 1.23 (0.82-1.83) 
130-139/85-89 High-prehypertension 1.29 (0.89-1.87) 1.38 (0.93-2.04) 
≥140/90  (no antihypertensive medication) 
Hypertension 
(Stages 1-2) 
1.44 (1.00-2.08) 2.01 (1.37-2.94) 
Use of antihypertensive medication 
Hypertension 
(Stages 1-2) 
1.83 (1.28-2.62) 2.24 (1.54-3.28) 
All covariates includes age, sex, and race/ethnicity, LDL, HDL, triglycerides, diabetes, HMG CoA reductase inhibitor use, HCV infection, renal disease, anemia, 
BMI, cocaine, and alcohol use 
† We included people with SBP<90 mmHg or DBP<60 mmHg as a separate category because in our cohort, such low blood pressure indicates hypotension 
instead of normotension. 
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Figure 7:  AMI rates per 10,000py by blood pressure category and HIV status illustrating additive interaction 
between blood pressure and HIV status on AMI rates.  
Bars represent 95% confidence intervals for rates. 
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Table 20: Rate & risk of incident AMI (95% CI) by  blood pressure and HIV status (common reference group) 
Blood Pressure  
Category (mmHg) 
Definition HIV status N # of AMIs 
Age/race adjusted  
AMI rate/10,000py 
Hazard Ratio (95% CI) 
 Adjusted for  
all covariates* 
<90/60† Hypotension
HIV- 441 4 19.54 (7.25-52.66) 1.68 (0.60-4.69) 
HIV+ 405 3 17.58 (5.61-55.04) 1.34 (0.41-4.34) 
90-119/60-79† Normal 
HIV- 7634 41 10.81 (7.75-15.1) 
1 
HIV+ 5722 41 15.53 (11.13-21.7) 1.30 (0.84-2.01) 
120-129/80-84 Low prehypertension 
HIV- 11503 64 11.06 (8.37-14.62) 1.00 (0.67-1.47) 
HIV+ 6310 59 19.08 (14.31-25.47) 1.60 (1.07-2.39) 
130-139/85-89 High prehypertension 
HIV- 11944 92 15.28 (11.99-19.5) 1.30 (0.90-1.88) 
HIV+ 5755 64 22.26 (16.88-29.4) 1.80 (1.21-2.68) 
≥140/90, no  
anti-hypertensive medication 
Hypertension 
(Stages 1-2) 
HIV- 11021 108 19.61 (15.6-24.69) 1.47 (1.02-2.12) 
HIV+ 4613 82 36.61 (28.4-47.29) 2.57 (1.76-3.76) 
Use of  
anti-hypertensive medication 
Hypertension 
(Stages 1-2) 
HIV- 11425 192 32.92 (27.31-39.77) 1.92 (1.35-2.73) 
HIV+ 4257 110 57.83 (46.27-72.41) 2.75 (1.89-4.00) 
All covariates includes age, sex, and race/ethnicity, LDL, HDL, triglycerides, diabetes, HMG CoA reductase inhibitor use, HCV infection, renal disease, anemia, 
BMI, cocaine, and alcohol use 
† We included people with SBP<90 mmHg or DBP<60 mmHg as a separate category because in our cohort, such low blood pressure indicates hypotension 
instead of normotension. 
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4.5 DISCUSSION 
In this cohort of Veterans, high prehypertension and hypertension were associated with 
an increased risk of AMI. Compared to normotensive uninfected Veterans, low and high 
prehypertension and hypertension were associated with increased risk of AMI. Both the absolute 
rates and relative risks of AMI were higher for HIV+ Veterans compared to uninfected Veterans 
within these elevated blood pressure categories. 
This is the first study to report an association between prehypertension and AMI risk 
among HIV+ Veterans. In the general population, prehypertension has been independently 
associated with cardiovascular events 
141,142
. We extend these findings to HIV+ Veterans using
an adjudicated, outcome, AMI.  
Whether HIV infection and/or its treatment interact with blood pressure to increase the 
risk of AMI is not clear. Prior studies examining the association between HIV, ART, and blood 
pressure are inconsistent 
143-145
. Our data suggest the presence of additive interaction between
HIV status and blood pressure on AMI risk. Such an interaction would be consistent with prior 
mechanistic studies reporting an association between HIV and renal disease
146
, endothelial
dysfunction
147
, reduced arterial elasticity
148
, and progression of atherosclerosis 
149-151
. The
indirect nature of this biological interaction may have contributed to the lack of a significant 
multiplicative interaction.  
Prior research has reported an association between hypertension and AMI risk among 
HIV+ people 
152,153
. This study extends those results by demonstrating that the relative rates and
risk of AMI are progressively higher with elevations in blood pressure among HIV+ compared to 
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uninfected Veterans. This study may not have had enough power to detect significant differences 
in AMI risk in regression models additionally stratified by HIV status (Table 19), though the 
trend in hazard ratios was similar to that seen for regression models using a common HIV 
uninfected normotensive reference group. 
Higher rates and risks of AMI observed among treated versus untreated hypertensive 
Veterans are challenging to interpret in the absence of data on duration of hypertension and/or 
treatment. 
Our findings have important clinical implications for HIV+ people. Prior work in the 
VACS and other studies demonstrate that HIV infection, ART use, and traditional CVD risk 
factors, including hypertension, are associated with an increased risk of AMI 
129
. Although HIV+
people have an increased risk of AMI (including those who achieve HIV-1 RNA levels <500 
copies/ml over time), as well as an increased risk of diabetes and renal disease compared to 
uninfected people, there are no HIV specific guidelines for AMI risk reduction beyond those for 
the general population
154
. In contrast, people with diabetes and/or chronic kidney disease, have
lower recommended blood pressure targets (i.e., blood pressure <130/80 compared to <140/90 
mmHg) in order to reduce the risk of future CVD events. Whether such recommendations would 
improve outcomes for HIV infected people is not known. However our data showing increased 
AMI risk among prehypertensive HIV+ Veterans suggests that such targets may be beneficial in 
this population.  
There are limitations that warrant discussion. First, as this is an observational study, our 
findings alone are insufficient to change current guidelines for blood pressure management for 
HIV infected people. Second, as our population is overwhelmingly male, our results may not be 
generalizable to women. Third, there is always the possibility of residual confounding present in 
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this analysis. For example, alcohol is associated with blood pressure and coronary heart disease 
outcomes. In this study, alcohol abuse and dependence was assessed with ICD-9 codes, which 
can result in some misclassification. However, the fact that alcohol use is common in both HIV+ 
and uninfected Veterans suggests that misclassification would not be differential. Fourth, blood 
pressure, HIV-1 RNA, and CD4+ cell count were assessed only at baseline. Participants could 
have moved between blood pressure, HIV-1 RNA, and/or CD4+ cell count categories between 
baseline and censoring. 
4.6 CONCLUSION 
In summary, prehypertensive and hypertensive blood pressure were associated with an 
increased risk of AMI in a cohort of HIV infected and uninfected Veterans. HIV may modify the 
association between hypertension and AMI risk. Given the increased risk of AMI, diabetes, and 
renal disease associated with HIV infection and if our results are confirmed in other studies, 
future research should explore whether lower blood pressure targets among HIV+ people 
translates into lower AMI risk in a randomized controlled trial. 
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5.0 THEMATIC SUMMARY 
In summary, this dissertation contributes insights into the pathogenesis of CHD in the 
setting of HIV infection. 
Prior studies have shown strong associations between inflammation and CHD risk and 
mortality. We have demonstrated that ongoing HIV replication and immune depletion and 
comorbid conditions like prevalent CVD and renal disease, contribute to elevated biomarkers 
associated with inflammation, altered coagulation, and monocyte activation. We have also 
described a different and potentially more complete method to describe an individual’s 
inflammatory state using a composite score with multiple inflammatory biomarkers. Our data 
suggest an interaction between blood pressure and HIV status on AMI risk such that people with 
elevated blood pressure and HIV infection have higher rates of AMI than would be expected 
from either alone. 
Taken together, these studies emphasizes the importance of studying HIV as a disease 
with pleiotropic effects – on multiple biomarkers and organ systems – that can interact with each 
other, modifying their independent contributions to CHD risk. An important question for future 
study is whether co-morbid diseases, traditionally associated with CVD, contribute to CVD risk 
to a similar degree and in a similar manner in HIV infected versus uninfected people, given 
differences in etiology of these co-morbid diseases. 
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APPENDIX 
SUPPLEMENTARY TABLES 
Table A1: PubMed search concepts and search terms for literature review describing effects of HIV infection 
on lipid and lipoprotein metabolism 
Search concept PubMed search terms 
Kinetic studies (((((((kinetic*) OR rate of reaction) OR rates of reaction)) OR 
((rate*) AND biochemical) OR tracer) OR compartment models) 
OR clearance rate) OR synthesis rate 
HIV ((((((hiv) OR hiv infection) OR human immunodeficiency virus) 
OR hiv seropositivity) OR hiv 1) OR hiv 2) OR acquired 
immune deficiency syndrome 
HIV uninfected ((((((seronegativity) OR seronegative) OR uninfected)) OR 
seroconversion) OR noninfected) OR hiv control group OR hiv 
negative 
Antiretroviral therapy 
naïve 
(hiv therapy naive) OR ((((((art naive) OR haart naive) OR 
untreated hiv) OR pre art) OR pre haart) OR antiretroviral 
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Search concept PubMed search terms 
therapy naive) 
Lipids/lipoproteins (((((((((lipid) OR lipids) OR lipid metabolism) OR lipid 
biosynthesis) OR lipid clearance) OR lipid immunology)) OR 
((((((lipoprotein) OR lipoproteins) OR lipoprotein metabolism) 
OR lipoprotein biosynthesis) OR lipoprotein clearance) OR lipid 
immunology))) OR ((((((((chylomicron) OR vldl) OR low 
density lipoprotein) OR ldl) OR high density lipoprotein) OR 
triglyceride*) OR fatty acid) OR cholesterol) 
Title pertaining to lipids or 
lipoproteins 
(((((((((((((((((((((((lipid[Title]) OR lipids[Title]) OR 
lipoprotein*[Title]) OR apolipoprotein*[Title]) OR hdl[Title]) 
OR ldl[Title]) OR vldl[Title]) OR idl[Title]) OR 
dyslipidemia*[Title]) OR dylipidaemia) OR 
lipodystrophy[Title]) OR lipoatrophy[Title]) OR 
lipohypertrophy[Title]) OR cholesterol*[Title]) OR 
hypercholesterolemia*[Title]) OR triglycerides*[Title]) OR 
hypertriglyceridemia*[Title]) OR hyperlipidemia*[Title]) OR 
metabolic[Title]) OR lipolysis[Title]) OR adipocyte*[Title]) OR 
fatty acid*[Title]) OR lipogenesis[Title]) OR 
hypocholesterolemia[Title] OR acute*phase[Title] 
Hypertriglyceridemia Hypertriglyceridemia 
Elevated free fatty acids (elevated OR high) AND (blood free fatty acids OR serum free 
fatty acids OR plasma free fatty acids) 
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Search concept PubMed search terms 
High density lipoprotein 
cholesterol reduction 
high density lipoprotein cholesterol reduction OR high density 
lipoprotein cholesterol decrease 
Low density lipoprotein 
cholesterol reduction 
low density lipoprotein cholesterol reduction OR low density 
lipoprotein cholesterol decrease 
Very low density 
lipoprotein cholesterol 
reduction 
very low density lipoprotein cholesterol reduction OR very low 
density lipoprotein cholesterol decrease 
Triglycerides triglycerides 
High density lipoprotein 
triglycerides 
high density lipoprotein triglycerides 
Low density lipoprotein 
triglycerides 
low density lipoprotein triglycerides 
Very low density 
lipoprotein triglycerides 
Very low density lipoprotein triglycerides 
Cell membrane structure ((((cell membrane structure) OR membrane fluidity) OR 
membrane microdomains)) OR lipid rafts 
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Table A2: Association of HIV/HCV group and covariates with individually elevated (>75th percentile) biomarkers. 
Odds Ratio (95% Confidence Interval) 
IL-10 TNF-α Cystatin C IL-6 CRP SAA IFN-γ MCP-1 
Undetectable 1 1 1 1 1 1 1 1 
HIV mono-detectable 
2.95 
(0.74, 11.85) 
4.44 
(0.86, 22.82) 
0.49 
(0.12, 2.02) 
0.57 
(0.15, 2.16) 
0.99 
(0.35, 2.84) 
0.58 
(0.19, 1.79) 
1.65 
(0.46, 5.87) 
2.96 
(0.80, 10.95) 
HCV mono-detectable 
5.51* 
(1.17, 25.84) 
4.45 
(0.68, 29.02) 
0.40 
(0.07, 2.34) 
2.99 
(0.75, 11.98) 
1.41 
(0.41, 4.90) 
0.38 
(0.09, 1.66) 
2.63 
(0.59, 11.76) 
3.71 
(0.83, 16.53) 
HIV/HCV detectable 
7.79* 
(1.90, 31.97) 
7.70* 
(1.42, 41.83) 
1.60 
(0.39, 6.57) 
1.47 
(0.40, 5.35) 
0.69 
(0.22, 2.14) 
0.72 
(0.22, 2.31) 
1.03 
(0.25, 4.30) 
3.48 
(0.88, 13.69) 
FIB-4 ≥ 1.45 
1.26 
(0.61, 2.62) 
2.07 
(0.93, 4.61) 
3.43* 
(1.45, 8.10) 
3.22* 
(1.44, 7.20) 
1.12 
(0.54, 2.32) 
1.13 
(0.51, 2.48) 
0.63 
(0.25, 1.61) 
2.39* 
(1.10, 5.20) 
High cholesterol 
1.27 
(0.58, 2.77) 
4.22* 
(1.85, 9.62) 
1.71 
(0.71, 4.11) 
0.90 
(0.37, 2.17) 
1.20 
(0.58, 2.51) 
1.13 
(0.50, 2.54) 
1.58 
(0.66, 3.80) 
1.81 
(0.79, 4.18) 
Age greater than median (42 years) 
0.42* 
(0.20, 0.87) 
0.47 
(0.21, 1.02) 
1.05 
(0.46, 2.41) 
0.74 
(0.33, 1.68) 
0.57 
(0.28, 1.14) 
1.82 
(0.87, 3.77) 
0.49 
(0.20, 1.17) 
0.97 
(0.46, 2.05) 
BMI ≥ 30 kg/m2 
0.57 
(0.22, 1.48) 
0.82 
(0.32, 2.10) 
1.11 
(0.40, 3.08) 
1.37 
(0.52, 3.60) 
2.33 
(1.03, 5.24) 
2.05 
(0.85, 4.95) 
0.47 
(0.15, 1.49) 
1.67 
(0.64, 4.38) 
Ever smoker 
1.02 
(0.45, 2.29) 
1.12 
(0.47, 2.69) 
3.71* 
(1.17, 11.72) 
1.33 
(0.52, 3.41) 
1.92 
(0.83, 4.45) 
1.57 
(0.66, 3.76) 
0.50 
(0.20, 1.23) 
0.73 
(0.32, 1.65) 
CD4 > 200 cells/mm3 
1.39 
(0.58, 3.34) 
1.72 
(0.64, 4.63) 
0.43 
(0.16, 1.17) 
0.87 
(0.32, 2.38) 
0.65 
(0.27, 1.57) 
0.50 
(0.20, 1.26) 
1.57 
(0.47, 5.26) 
0.53 
(0.22, 1.27) 
Renal disease 
1.24 
(0.32, 4.83) 
2.18 
(0.54, 8.79) 
9.47* 
(2.06, 43.48) 
2.09 
(0.45, 9.69) 
1.15 
(0.30, 4.35) 
5.17* 
(1.23, 21.69) 
2.79 
(0.58, 13.38) 
0.14 
(0.02, 1.23) 
Diabetes 
0.91 
(0.20, 4.04) 
4.88* 
(1.18, 20.21) 
4.91 
(0.98, 24.65) 
3.33 
(0.69, 16.11) 
3.68 
(0.97, 14.02) 
1.26 
(0.27, 5.93) 
--** 
(--) 
1.08 
(0.25, 4.60) 
Current antiretroviral therapy use 
0.62 
(0.29, 1.30) 
0.38* 
(0.16, 0.86) 
0.44 
(0.18, 1.07) 
0.81 
(0.34, 1.92) 
1.04 
(0.50, 2.20) 
1.07 
(0.49, 2.33) 
1.43 
(0.56, 3.65) 
1.30 
(0.59, 2.90) 
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Odds Ratio (95% Confidence Interval) 
IL-10 TNF-α Cystatin C IL-6 CRP SAA IFN-γ MCP-1 
Prevalent cardiovascular disease 
0.34 
(0.06, 1.84) 
3.64 
(0.88, 14.98) 
4.56* 
(1.02, 20.43) 
0.32 
(0.03, 3.08) 
1.83 
(0.44, 7.64) 
1.61 
(0.38, 6.89) 
2.73 
(0.54, 13.66) 
0.35 
(0.06, 2.13) 
Hypertension 
0.97 
(0.42, 2.26) 
0.79 
(0.32, 1.92) 
1.09 
(0.43, 2.80) 
0.59 
(0.22, 1.58) 
0.66 
(0.29, 1.51) 
0.51 
(0.20, 1.28) 
1.10 
(0.41, 2.96) 
0.84 
(0.33, 2.08) 
At-risk alcohol consumption 
0.75 
(0.36, 1.55) 
0.80 
(0.37, 1.74) 
0.99 
(0.43, 2.29) 
1.79 
(0.78, 4.08) 
1.06 
(0.52, 2.14) 
1.13 
(0.53, 2.38) 
1.50 
(0.61, 3.65) 
0.63 
(0.29, 1.38) 
Female 
0.79 
(0.34, 1.82) 
1.26 
(0.53, 3.03) 
1.47 
(0.59, 3.66) 
1.21 
(0.50, 2.92) 
1.01 
(0.45, 2.26) 
1.62 
(0.69, 3.80) 
1.36 
(0.49, 3.80) 
0.17* 
(0.05, 0.60) 
*p-value <0.05;
**There were no elevated IFN-γ outcomes among those with diabetes. 
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Table A3: AMI risk and blood pressure category adjusted for HIV-1 RNA (< or ≥500 copies/mL) or CD4+ T-lymphocyte count (cells/mm3) and 
HAART use among HIV infected Veterans 
Blood Pressure  
Category (mmHg) 
Definition HIV status 
Hazard Ratio (95% CI) 
All covariates +HAART 
All covariates, HAART, 
CD4 cell count, HIV-1 
RNA 
<90/60† Hypotension HIV+ 
1.05 (0.32-3.38) 
1.04 (0.32-3.37) 
90-119/60-79† Normal HIV+ 1 1 
120-129/80-84 Low prehypertension HIV+ 1.23 (0.82-1.83) 1.24 (0.83-1.85) 
130-139/85-89 High-prehypertension HIV+ 1.38 (0.93-2.04) 1.39 (0.94-2.05) 
≥140/90 
Hypertension 
(Stages 1-2) 
HIV+ 2.01 (1.37-2.93) 2.02 (1.38-2.96) 
Use of antihypertensive medication HIV+ 2.24 (1.54-3.28) 2.28 (1.56-3.33) 
All models adjust for age, sex, and race/ethnicity, LDL, HDL, triglycerides, diabetes, HMG CoA reductase inhibitor use, HCV infection, renal disease, anemia, 
BMI, cocaine, and alcohol use. 
† We included people with SBP<90 mmHg or DBP<60 mmHg as a separate category because in our cohort, such low blood pressure indicates hypotension 
instead of normotension. 
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Table A4: Rate & risk of incident AMI (95% CI) by a) systolic blood pressure (SBP) or b) diastolic blood pressure (DBP) and HIV status 
a) Systolic Blood Pressure
Category (mmHg) 
Definition HIV status N # of AMIs 
Age/race adjusted  
AMI rate/10,000py 
Hazard Ratio (95% CI) 
Adjusted for all covariates* 
<90† Hypotension 
HIV- 19 0 -- -- 
HIV+ 41 2 179.93 (44.62-
725.64) 
9.79 (2.32-41.34) 
90-119† Normal 
HIV- 8735 48 11.13 (8.15-15.22) 1 
HIV+ 6521 45 15.02 (10.9-20.72) 1.22 (0.81-1.84) 
120-129 Low prehypertension 
HIV- 11945 71 11.85 (9.08-15.49) 1.04 (0.72-1.5) 
HIV+ 6466 64 20.24 (15.33-26.78) 1.65 (1.13-2.4) 
130-139 High-prehypertension 
HIV- 11975 91 15.07 (11.81-19.25) 1.24 (0.87-1.76) 
HIV+ 5712 68 23.85 (18.21-31.28) 1.87 (1.29-2.71) 
≥140 
Hypertension (Stages 1-2) 
HIV- 9869 99 19.98 (15.78-25.36) 1.43 (1.01-2.03) 
HIV+ 4065 70 35.11 (26.8-46.09) 2.34 (1.61-3.39) 
Use of  
antihypertensive medication 
HIV- 11525 193 32.87 (27.28-39.69) 1.86 (1.34-2.59) 
HIV+ 4256 110 57.53 (46.03-72.03) 2.68 (1.88-3.81) 
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b) Diastolic Blood Pressure
Category (mmHg) 
Definition HIV status N # of AMIs 
Age/race adjusted  
AMI rate/10,000py 
Hazard Ratio (95% CI) 
Adjusted for all covariates* 
<60† Hypotension
HIV- 554 
6 
22.87 (10.12-51.68) 1.75 (0.77-3.96) 
HIV+ 463 
3 
15.06 (4.8-47.23) 0.98 (0.31-3.1) 
60-79† Normal 
HIV- 23063 
145 
12.49 (10.13-15.44) 1 
HIV+ 13753 
125 
18.78 (15.09-23.42) 1.43 (1.11-1.82) 
80-84 Low prehypertension 
HIV- 8869 
70 
15.52 (11.88-20.32) 1.23 (0.92-1.64) 
HIV+ 4211 
52 
25.07 (18.54-33.95) 1.89 (1.37-2.61) 
85-89 High-prehypertension 
HIV- 5586 
49 
17.63 (12.96-24.03) 1.42 (1.03-1.96) 
HIV+ 2511 
35 
28.29 (19.84-40.38) 2.17 (1.5-3.15) 
≥90 
Hypertension (Stages 1-2) 
HIV- 
4471 39 
18.15 (12.96-25.44) 1.42 (1-2.03) 
HIV+ 1867 
34 
39.91 (27.83-57.3) 2.91 (2-4.24) 
Use of 
antihypertensive medication 
HIV- 11525 
193 
32.89 (27.29-39.73) 1.78 (1.42-2.23) 
HIV+ 4285 
110 57.56 (46.04-72.08) 
2.57 (1.97-3.35) 
All covariates includes age, sex, and race/ethnicity, LDL, HDL, triglycerides, diabetes, HMG CoA reductase inhibitor use, HCV infection, renal disease, anemia, 
BMI, cocaine, and alcohol use 
† We included people with SBP<90 mmHg or DBP<60 mmHg as a separate category because in our cohort, such low blood pressure indicates hypotension 
instead of normotension. 
Table A4 continued
113 
BIBLIOGRAPHY 
1. Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on
lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res
2004;45:1169-96.
2. Beisel WR. Metabolic response to infection. Annual review of medicine 1975;26:9-20.
3. Beisel WR. Magnitude of the host nutritional responses to infection. Am J Clin Nutr
1977;30:1236-47.
4. Bostian KA, Blackburn BS, Wannemacher RW, Jr., McGann VG, Beisel WR, Dupont HL.
Sequential changes in the concentration of specific serum proteins during typhoid fever
infection in man. J Lab Clin Med 1976;87:577-85.
5. Powanda MC, Beisel WR. Metabolic effects of infection on protein and energy status. J
Nutr 2003;133:322S-7S.
6. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN, Jr. Effect of home
total parenteral nutrition on body composition in patients with acquired immunodeficiency
syndrome. JPEN J Parenter Enteral Nutr 1990;14:454-8.
7. Macallan DC, McNurlan MA, Milne E, Calder AG, Garlick PJ, Griffin GE. Whole-body
protein turnover from leucine kinetics and the response to nutrition in human
immunodeficiency virus infection. Am J Clin Nutr 1995;61:818-26.
8. Hommes MJ, Romijn JA, Endert E, Sauerwein HP. Resting energy expenditure and
substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men:
HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr
1991;54:311-5.
9. Sharpstone DR, Murray CP, Ross HM, et al. Energy balance in asymptomatic HIV
infection. AIDS 1996;10:1377-84.
10. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy
expenditure, caloric intake, and short-term weight change in human immunodeficiency
virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr
1992;55:455-60.
11. Hommes MJ, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in
human immunodeficiency virus-infected men. Metabolism 1990;39:1186-90.
12. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human
immunodeficiency virus infection. N Engl J Med 1995;333:83-8.
13. Piche T, Schneider SM, Tran A, Benzaken S, Rampal P, Hebuterne X. Resting energy
expenditure in chronic hepatitis C. J Hepatol 2000;33:623-7.
14. Schwenk A, Hodgson L, Rayner CF, Griffin GE, Macallan DC. Leptin and energy
metabolism in pulmonary tuberculosis. Am J Clin Nutr 2003;77:392-8.
114 
15. Chan DC, Barrett PH, Watts GF. Lipoprotein transport in the metabolic syndrome:
methodological aspects of stable isotope kinetic studies. Clin Sci (Lond) 2004;107:221-32.
16. Shahmanesh M, Das S, Stolinski M, et al. Antiretroviral treatment reduces very-low-
density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional
catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J
Clin Endocrinol Metab 2005;90:755-60.
17. Umpleby AM, Das S, Stolinski M, et al. Low density lipoprotein apolipoprotein B
metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. Antivir
Ther 2005;10:663-70.
18. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF. Mechanism of highly active
anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis
2005;178:165-72.
19. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids,
lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus
infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab
1992;74:1045-52.
20. Van Veldhoven PP, Matthews TJ, Bolognesi DP, Bell RM. Changes in bioactive lipids,
alkylacylglycerol and ceramide, occur in HIV-infected cells. Biochem Biophys Res
Commun 1992;187:209-16.
21. Lynn WS, Tweedale A, Cloyd MW. Human immunodeficiency virus (HIV-1) cytotoxicity:
perturbation of the cell membrane and depression of phospholipid synthesis. Virology
1988;163:43-51.
22. Jahoor F, Gazzard B, Phillips G, et al. The acute-phase protein response to human
immunodeficiency virus infection in human subjects. Am J Physiol 1999;276:E1092-8.
23. Jahoor F, Abramson S, Heird WC. The protein metabolic response to HIV infection in
young children. Am J Clin Nutr 2003;78:182-9.
24. Manes S, del Real G, Lacalle RA, et al. Membrane raft microdomains mediate lateral
assemblies required for HIV-1 infection. EMBO reports 2000;1:190-6.
25. Campbell SM, Crowe SM, Mak J. Lipid rafts and HIV-1: from viral entry to assembly of
progeny virions. J Clin Virol 2001;22:217-27.
26. Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage
cholesterol metabolism. J Leukoc Biol 2006;80:1044-51.
27. Manes S, del Real G, Martinez AC. Pathogens: raft hijackers. Nat Rev Immunol
2003;3:557-68.
28. Aloia RC, Tian H, Jensen FC. Lipid composition and fluidity of the human
immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U
S A 1993;90:5181-5.
29. Nguyen DH, Hildreth JE. Evidence for budding of human immunodeficiency virus type 1
selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000;74:3264-72.
30. Alfsen A, Iniguez P, Bouguyon E, Bomsel M. Secretory IgA specific for a conserved
epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol
2001;166:6257-65.
31. Maziere JC, Landureau JC, Giral P, et al. Lovastatin inhibits HIV-1 expression in H9
human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother
1994;48:63-7.
115 
32. Lingwood D, Simons K. Lipid rafts as a membrane-organizing principle. Science
2010;327:46-50.
33. Yethiraj A, Weisshaar JC. Why are lipid rafts not observed in vivo? Biophys J
2007;93:3113-9.
34. Munro S. Lipid rafts: elusive or illusive? Cell 2003;115:377-88.
35. Brugger B, Glass B, Haberkant P, Leibrecht I, Wieland FT, Krausslich HG. The HIV
lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A 2006;103:2641-6.
36. Simons K, Toomre D. Lipid rafts and signal transduction. Nature reviews Molecular cell
biology 2000;1:31-9.
37. Simons K, Gerl MJ. Revitalizing membrane rafts: new tools and insights. Nature reviews
Molecular cell biology 2010;11:688-99.
38. Peterlin BM, Trono D. Hide, shield and strike back: how HIV-infected cells avoid immune
eradication. Nat Rev Immunol 2003;3:97-107.
39. Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects
the macrophage CD40L signalling pathway to promote resting-cell infection. Nature
2003;424:213-9.
40. Grassme H, Jendrossek V, Bock J, Riehle A, Gulbins E. Ceramide-rich membrane rafts
mediate CD40 clustering. J Immunol 2002;168:298-307.
41. Wang L, Sapuri-Butti AR, Aung HH, Parikh AN, Rutledge JC. Triglyceride-rich
lipoprotein lipolysis increases aggregation of endothelial cell membrane microdomains and
produces reactive oxygen species. Am J Physiol Heart Circ Physiol 2008;295:H237-44.
42. Eggesbo JB, Hagve TA, Borsum K, Hostmark AT, Hjermann I, Kierulf P. Lipid
composition of mononuclear cell membranes and serum from persons with high or low
levels of serum HDL cholesterol. Scand J Clin Lab Invest 1996;56:199-210.
43. Puff N, Lamaziere A, Seigneuret M, Trugnan G, Angelova MI. HDLs induce raft domain
vanishing in heterogeneous giant vesicles. Chemistry and physics of lipids 2005;133:195-
202. 
44. Peng Y, Akmentin W, Connelly MA, Lund-Katz S, Phillips MC, Williams DL. Scavenger
receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasma
membrane domain is a way station for cholesterol trafficking between cells and high-
density lipoprotein. Mol Biol Cell 2004;15:384-96.
45. Girona J, LaVille AE, Sola R, Motta C, Masana L. HDL derived from the different phases
of conjugated diene formation reduces membrane fluidity and contributes to a decrease in
free cholesterol efflux from human THP-1 macrophages. Biochim Biophys Acta
2003;1633:143-8.
46. Kuehl KS, Yeroushalmy S, Holloway PW. Modulation of membrane composition of swine
vascular smooth muscle cells by homologous lipoproteins in culture. Biochim Biophys
Acta 1980;600:689-700.
47. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids
in men. JAMA 2003;289:2978-82.
48. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin
(EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for
managing patients with moderate hypercholesterolemia. Am J Med 1991;91:18S-24S.
49. Pritchard KA, Jr., Schwarz SM, Medow MS, Stemerman MB. Effect of low-density
lipoprotein on endothelial cell membrane fluidity and mononuclear cell attachment. Am J
Physiol 1991;260:C43-9.
116 
50. Patschan S, Li H, Brodsky S, et al. Probing lipid rafts with proximity imaging: actions of
proatherogenic stimuli. Am J Physiol Heart Circ Physiol 2006;290:H2210-9.
51. Orso E, Grandl M, Schmitz G. Oxidized LDL-induced endolysosomal phospholipidosis
and enzymatically modified LDL-induced foam cell formation determine specific lipid
species modulation in human macrophages. Chemistry and physics of lipids 2011;164:479-
87.
52. Megha, Bakht O, London E. Cholesterol precursors stabilize ordinary and ceramide-rich
ordered lipid domains (lipid rafts) to different degrees. Implications for the Bloch
hypothesis and sterol biosynthesis disorders. J Biol Chem 2006;281:21903-13.
53. Shentu TP, Titushkin I, Singh DK, et al. oxLDL-induced decrease in lipid order of
membrane domains is inversely correlated with endothelial stiffness and network
formation. American journal of physiology Cell physiology 2010;299:C218-29.
54. Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-
infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy.
HIV Clin Trials 2006;7:41-7.
55. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is
related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscler
Thromb Vasc Biol 2000;20:E63-7.
56. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of
antiretroviral treatment. N Engl J Med 2006;355:2283-96.
57. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict
myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler
Thromb Vasc Biol 1999;19:493-8.
58. Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein, interleukin-6, and fibrinogen as
predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol
2003;23:1255-61.
59. Wannamethee SG, Whincup PH, Shaper AG, Rumley A, Lennon L, Lowe GD. Circulating
inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction
and coronary death, but not angina pectoris, in older men. J Thromb Haemost 2009;7:1605-
11.
60. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6
and the risk of future myocardial infarction among apparently healthy men. Circulation
2000;101:1767-72.
61. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and
mortality in patients with HIV infection. PLoS Med 2008;5:e203.
62. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict
incident cardiovascular disease events in chronic HIV infection. AIDS 2010;24:1509-17.
63. Baker J, Quick H, Hullsiek KH, et al. Interleukin-6 and d-dimer levels are associated with
vascular dysfunction in patients with untreated HIV infection. HIV Med 2010;11:608-9.
64. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection
with acute myocardial infarction. J Acquir Immune Defic Syndr 2009;51:268-73.
65. Sandler NG, Wand H, Roque A, et al. Plasma Levels of Soluble CD14 Independently
Predict Mortality in HIV Infection. J Infect Dis 2011.
66. Raj DS, Carrero JJ, Shah VO, et al. Soluble CD14 levels, interleukin 6, and mortality
among prevalent hemodialysis patients. Am J Kidney Dis 2009;54:1072-80.
117 
67. Neuhaus J, Jacobs DR, Jr., Baker JV, et al. Markers of inflammation, coagulation, and
renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-95.
68. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of
inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis
2010;201:285-92.
69. Cassol E, Malfeld S, Mahasha P, et al. Persistent microbial translocation and immune
activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J
Infect Dis 2010;202:723-33.
70. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS):
Overview and description. Med Care 2006;44:S13-24.
71. Every NR, Fihn SD, Sales AE, Keane A, Ritchie JR. Quality Enhancement Research
Initiative in ischemic heart disease: a quality initiative from the Department of Veterans
Affairs. QUERI IHD Executive Committee. Med Care 2000;38:I49-59.
72. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular
events. The Cardiovascular Health Study. Ann Epidemiol 1995;5:278-85.
73. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure:
the JNC 7 report. JAMA 2003;289:2560-72.
74. Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of
diabetes mellitus. AIDS 2009;23:1227-34.
75. McGinnis KA, Brandt CA, Skanderson M, et al. Validating Smoking Data From the
Veteran's Affairs Health Factors Dataset, an Electronic Data Source. Nicotine Tob Res
2011. 
76. Executive Summary of The Third Report of The National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol
In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
77. Freiberg MS, McGinnis KA, Kraemer K, et al. The association between alcohol
consumption and prevalent cardiovascular diseases among HIV-infected and HIV-
uninfected men. J Acquir Immune Defic Syndr 2010;53:247-53.
78. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and
treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans.
AIDS (London, England) 2005;19 Suppl 3:S99-105.
79. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification,
and stratification. Am J Kidney Dis 2002;39:S1-266.
80. Royston P. Multiple imputation of missing values: further update of ice, with an emphasis
on interval censoring. Stata Journal 2007:445-64.
81. Thorand B, Lowel H, Schneider A, et al. C-reactive protein as a predictor for incident
diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort
study, 1984-1998. Arch Intern Med 2003;163:93-9.
82. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6,
and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
83. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently
healthy men. Hypertension 2001;38:399-403.
84. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1
expression and activity in human aortic endothelial cells: implications for the metabolic
syndrome and atherothrombosis. Circulation 2003;107:398-404.
118 
85. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the
interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost
2003;89:493-8.
86. Varughese GI, Lip GY. Is hypertension a prothrombotic state? Curr Hypertens Rep
2005;7:168-73.
87. de Kort S, Keszthelyi D, Masclee AA. Leaky gut and diabetes mellitus: what is the link?
Obes Rev 2011;12:449-58.
88. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic
endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.
Diabetes 2008;57:1470-81.
89. Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. Elevated levels of serum-
soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to
disease progression and clinical events. Blood 1998;92:2084-92.
90. Wallet MA, Rodriguez CA, Yin L, et al. Microbial translocation induces persistent
macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.
AIDS 2010;24:1281-90.
91. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of
HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004;200:749-
59.
92. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid
tissue during primary human immunodeficiency virus type 1 infection and substantial delay
in restoration following highly active antiretroviral therapy. J Virol 2003;77:11708-17.
93. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related
microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226-33.
94. Freiberg MS, Chang CC, Skanderson M, et al. The Risk of Incident Coronary Heart
Disease Among Veterans With and Without HIV and Hepatitis C. Circ Cardiovasc Qual
Outcomes 2011;4:425-32.
95. Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus
coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med
2010;11:462-8.
96. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus
infection and the risk of coronary disease. Clin Infect Dis 2009;49:225-32.
97. Freiberg MS, Cheng DM, Kraemer KL, Saitz R, Kuller LH, Samet JH. The association
between hepatitis C infection and prevalent cardiovascular disease among HIV-infected
individuals. AIDS 2007;21:193-7.
98. Justice AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect
effects of inflammation, coagulation, and monocyte activation on mortality among those
aging with HIV? Clin Infect Dis 2012;54:984-94.
99. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R. Alcohol consumption
and HIV disease progression. J Acquir Immune Defic Syndr 2007;46:194-9.
100. Samet JH, Phillips SJ, Horton NJ, Traphagen ET, Freedberg KA. Detecting alcohol 
problems in HIV-infected patients: use of the CAGE questionnaire. AIDS Res Hum 
Retroviruses 2004;20:151-5. 
101. Smith KL, Horton NJ, Saitz R, Samet JH. The use of the mini-mental state examination in 
recruitment for substance abuse research studies. Drug Alcohol Depend 2006;82:231-7. 
119 
102. Armah KA, McGinnis K, Baker J, et al. HIV Status, Burden of Comorbid Disease and 
Biomarkers of Inflammation, Altered Coagulation and Monocyte Activation. Clin Infect 
Dis 2012. 
103. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of 
inflammation in the prediction of cardiovascular disease in women. N Engl J Med 
2000;342:836-43. 
104. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary 
heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention 
Trial. Am J Epidemiol 1996;144:537-47. 
105. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice 
reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894-7. 
106. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are 
independent predictors of the development of opportunistic disease in patients with HIV 
infection. J Infect Dis 2009;200:973-83. 
107. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein 
formation. J Exp Med 1966;123:365-78. 
108. Morrow JF, Stearman RS, Peltzman CG, Potter DA. Induction of hepatic synthesis of 
serum amyloid A protein and actin. Proc Natl Acad Sci U S A 1981;78:4718-22. 
109. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in 
plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr 
Hum Retrovirol 1995;8:446-54. 
110. Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL. Screening for 
hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 
2000;38:575-7. 
111. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to 
predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 
2006;43:1317-25. 
112. Sobell MB, Sobell LC, Klajner F, Pavan D, Basian E. The reliability of a timeline method 
for assessing normal drinker college students' recent drinking history: utility for alcohol 
research. Addict Behav 1986;11:149-61. 
113. NIAAA. Helping Patients Who Drink Too Much. A clinician's guide. 2005. 
114. D. Fuster JIT, D.M. Cheng, E.K Quinn, K. Armah, D. Nunes, M.S. Freiberg, J.H. Samet. . 
Inflammatory cytokines (IL-6, IL-10, TNF-alpha), Hepatitis C Virus (HCV) and liver 
fibrosis in HIV-infected patients with alcohol problems. . In: HIV and the Liver Meeting 
2012. Jackson Hole, Wyoming; 2012. 
115. Blackard JT, Kang M, St Clair JB, et al. Viral factors associated with cytokine expression 
during HCV/HIV co-infection. J Interferon Cytokine Res 2007;27:263-9. 
116. El-Hage N, Dever SM, Fitting S, Ahmed T, Hauser KF. HIV-1 coinfection and morphine 
coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory 
cytokine release and free radical production: increased pathogenesis coincides with 
uncoordinated host defenses. J Virol 2011;85:11601-14. 
117. Graham CS, Curry M, He Q, et al. Comparison of HCV-specific intrahepatic CD4+ T cells 
in HIV/HCV versus HCV. Hepatology 2004;40:125-32. 
118. Blackard JT, Komurian-Pradel F, Perret M, et al. Intrahepatic cytokine expression is 
downregulated during HCV/HIV co-infection. J Med Virol 2006;78:202-7. 
120 
119. Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C 
infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-
infected men. AIDS Patient Care STDS 2007;21:479-91. 
120. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV 
coinfection with C-reactive protein levels: the fat redistribution and metabolic change in 
HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008;48:142-8. 
121. Barrett L, Gallant M, Howley C, et al. Enhanced IL-10 production in response to hepatitis 
C virus proteins by peripheral blood mononuclear cells from human immunodeficiency 
virus-monoinfected individuals. BMC Immunol 2008;9:28. 
122. Cribier B, Schmitt C, Rey D, Lang JM, Kirn A, Stoll-Keller F. Production of cytokines in 
patients infected by hepatitis C virus. J Med Virol 1998;55:89-91. 
123. Lapinski TW, Parfieniuk A, Rogalska-Plonska M, Czajkowska J, Flisiak R. Prevalence of 
cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency 
virus-infected individuals: implications for renal function. Liver Int 2009;29:1158-61. 
124. Gonzalez SA, Zhang C, Fiel MI, et al. Hepatic inflammatory cytokine mRNA expression in 
hepatitis C virus-human immunodeficiency virus co-infection. J Viral Hepat 2008;15:331-
8. 
125. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. 
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 2006;12:1301-9. 
126. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J 
Hepatol 2006;44:S132-9. 
127. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and 
cardiovascular disease: application to clinical and public health practice: A statement for 
healthcare professionals from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation 2003;107:499-511. 
128. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 
Hypertension 2003;42:1206-52. 
129. Freiberg MS, Chang CC, Kuller LH, et al. HIV Infection and the Risk of Acute Myocardial 
Infarction. JAMA internal medicine 2013:1-9. 
130. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-
infected patients in France, relative to the general population. AIDS 2010;24:1228-30 
10.097/QAD.0b013e328339192f. 
131. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV 
infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and 
nested case-control study using Quebec's public health insurance database. J Acquir 
Immune Defic Syndr 2011;57:245-53. 
132. Gutierrez AD, Balasubramanyam A. Dysregulation of glucose metabolism in HIV patients: 
epidemiology, mechanisms, and management. Endocrine 2012;41:1-10. 
133. Winston J, Klotman PE. HIV-associated nephropathy. Mt Sinai J Med 1998;65:27-32. 
134. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" 
cohort using the National VA Health Information System. Med Care 2006;44:S25-30. 
135. Ischemic Heart Disease (IHD) Quality Enhancement Research Initiative. 2011. (Accessed 
at http://www.queri.research.va.gov/ihd/default.cfm.) 
121 
136. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of 
acute myocardial infarction in an administrative database. J Gen Intern Med 1999;14:555-
8. 
137. The sixth report of the Joint National Committee on prevention, detection, evaluation, and 
treatment of high blood pressure. Arch Intern Med 1997;157:2413-46. 
138. Maynard C, Lowy E, Rumsfeld J, et al. The prevalence and outcomes of in-hospital acute 
myocardial infarction in the Department of Veterans Affairs Health System. Archives of 
internal medicine 2006;166:1410-6. 
139. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in 
HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology 
2004;40:115-9. 
140. Kraemer KL, McGinnis KA, Skanderson M, et al. Alcohol problems and health care 
services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected 
veterans. Med Care 2006;44:S44-51. 
141. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of 
cardiovascular disease. N Engl J Med 2001;345:1291-7. 
142. Liszka HA, Mainous AG, 3rd, King DE, Everett CJ, Egan BM. Prehypertension and 
cardiovascular morbidity. Annals of family medicine 2005;3:294-9. 
143. Thiebaut R, El-Sadr WM, Friis-Moller N, et al. Predictors of hypertension and changes of 
blood pressure in HIV-infected patients. Antivir Ther 2005;10:811-23. 
144. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral 
therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 
2005;19:953-60. 
145. Khalsa A, Karim R, Mack WJ, et al. Correlates of prevalent hypertension in a large cohort 
of HIV-infected women: Women's Interagency HIV Study. AIDS 2007;21:2539-41. 
146. Phair J, Palella F. Renal disease in HIV-infected individuals. Curr Opin HIV AIDS 
2011;6:285-9. 
147. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human 
immunodeficiency virus-infected antiretroviral-naive subjects before and after starting 
potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am 
Coll Cardiol 2008;52:569-76. 
148. Baker JV, Duprez D, Rapkin J, et al. Untreated HIV infection and large and small artery 
elasticity. J Acquir Immune Defic Syndr 2009;52:25-31. 
149. Baker JV, Henry WK, Patel P, et al. Progression of carotid intima-media thickness in a 
contemporary human immunodeficiency virus cohort. Clin Infect Dis 2011;53:826-35. 
150. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid 
intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-8. 
151. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary 
atherosclerosis detected by coronary computed tomography angiography in HIV-infected 
men. AIDS 2010;24:243-53. 
152. Friis-Moller N, Thiebaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in 
HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. 
Eur J Cardiovasc Prev Rehabil 2010;17:491-501. 
153. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute 
myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy 
era. Clin Infect Dis 2011;53:84-91. 
122 
154. Stein JH, Hadigan CM, Brown TT, et al. Prevention strategies for cardiovascular disease in 
HIV-infected patients. Circulation 2008;118:e54-60. 
